

CITATION REPORT

List of articles citing

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

DOI: 10.1056/nejmoa1613683

New England Journal of Medicine, 2017, 376, 1015-1026.

Source: <https://exaly.com/paper-pdf/66040335/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2224	PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017 , 376, 1073-1074	59.2	36
2223	Bladder cancer: Pembrolizumab is superior to chemotherapy. 2017 , 14, 261		6
2222	Immunotherapy: a new treatment paradigm in bladder cancer. 2017 , 29, 184-195		33
2221	Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. 2017 , 471, 271-280		13
2220	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. 2017 , 15, 509-512.e9		1
2219	Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. 2017 , 72, 477-481		28
2218	Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. 2017 , 77, 1077-1089		53
2217	Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. 2017 , 9, 463-466		0
2216	Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas. 2017 , 35, 462-464		10
2215	[The role of immunooncology in the treatment of urothelial cancer]. 2017 , 48, 329-335		
2214	Pembrolizumab for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017 , 376, 2302	59.2	8
2213	Reply to Pontus Eriksson, Gottfrid Sjöbahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. <i>J Clin Oncol</i> 2017 ;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein Expression L. 2017 , 72, e137-e138		2
2212	Targeted therapies in the treatment of urothelial cancers. 2017 , 35, 465-472		13
2211	Chemotherapy for advanced urothelial cancer: end of the beginning?. 2017 , 18, 567-569		7
2210	Mechanistic and pharmacologic insights on immune checkpoint inhibitors. 2017 , 120, 1-9		29
2209	Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. 2017 , 18, 672-681a		32
2208	Urological cancer: Unravelling intertwined second-line options. 2017 , 14, 197		

2207	Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). 2017 , 9, 1309-1321	35
2206	Update of systemic immunotherapy for advanced urothelial carcinoma. 2017 , 35, 678-686	10
2205	Prospects for precision therapy of bladder urothelial carcinoma. 2017 , 2, 261-274	1
2204	Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. 2017 , 9, 1175-1183	26
2203	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. 2017 , 2, e000236	19
2202	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 2017 , 15, 1240-1267	172
2201	Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy. 2017 , 15, 1277-1284	20
2200	Immuno-oncology in urothelial carcinoma: who or what will ultimately sit on the iron throne?. 2017 , 9, 951-954	5
2199	A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma. 2017 , 37, 1391-1405	11
2198	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. 2017 , 18, 1483-1492	688
2197	Atezolizumab in invasive and metastatic urothelial carcinoma. 2017 , 10, 1295-1301	8
2196	Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma. 2017 , 108, 2430-2437	12
2195	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. 2017 , 15, 205	13
2194	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. 2017 , 86, 257-265	21
2193	Prospects and progress of immunotherapy for bladder cancer. 2017 , 17, 1417-1431	21
2192	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). 2017 , 84, 212-218	78
2191	Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. 2017 , 28, 2458-2463	49
2190	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. 2017 , 117, 913-920	111

2189	Trial watch: Immune checkpoint blockers for cancer therapy. 2017 , 6, e1373237	53
2188	Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. 2017 , 9, 781-784	2
2187	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. 2017 , 390, 2266-2277	121
2186	Identification of prognostic genes through expression differentiation during metastatic process in lung adenocarcinoma. 2017 , 7, 11119	1
2185	Antiangiogenesis to curb urothelial cancer. 2017 , 390, 2220-2221	4
2184	Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors. 2017 , 12, 1626-1635	55
2183	Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer. 2017 , 34, 170	26
2182	Immunotherapy in genitourinary cancers: where are we going?. 2017 , 2, 73-78	2
2181	New treatment options for metastatic renal cell carcinoma. 2017 , 2, e000185	49
2180	Nivolumab for the treatment of bladder cancer. 2017 , 17, 1309-1315	10
2179	Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatersen and chemotherapy for patients with advanced urothelial cancer. 2017 , 28, 2481-2488	15
2178	Efficacité du pembrolizumab en deuxième ligne de traitement des carcinomes urothéliaux avancés. 2017 , 27, F38-F39	
2177	Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. 2017 , 44, 132-135	64
2176	Cancer Immunotherapies: Are They as Effective in the Elderly?. 2017 , 34, 567-581	22
2175	[Role of the human ErbB family receptors in urothelial carcinoma of the bladder: mRNA expression status and prognostic relevance]. 2017 , 48, 356-362	2
2174	Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer. 2017 , 18, 1167-1178	5
2173	Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration. 2017 , 28, 2895-2896	24
2172	The importance for immunoregulation for long-term cancer control. 2017 , 13, 1619-1632	8

2171	Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. 2017 , 3, e172411	572
2170	Hypothyroid ataxia complicating monoclonal antibody therapy. 2017 , 17, 482-484	3
2169	Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. 2017 , 11, 1178223417731565	25
2168	Complications rhumatologiques de l'immunothérapie anticancéreuse. 2017 , 84, A29-A33	
2167	Checkpoint inhibition in pediatric hematologic malignancies. 2017 , 34, 379-394	16
2166	Quality matters: immunotherapy and the evolving landscape of advanced cancer care. 2017 , 2, 235-244	2
2165	Immunotherapie urologischer Tumoren. 2017 , 20, 28-35	
2164	Therapeutics: Spoilt for choice. 2017 , 551, S36-S38	2
2163	Pembrolizumab in the treatment of advanced urothelial cancer. 2017 , 13, 2745-2758	4
2162	Cardiotoxicity of immune checkpoint inhibitors. 2017 , 2, e000247	126
2161	Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. 2017 , 92, 1564-1582	18
2160	Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. 2017 , 16, 272-294	3
2159	Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. 2017 , 72, 411-423	61
2158	Immune checkpoint inhibitors and elderly people: A review. 2017 , 82, 155-166	99
2157	Landmarks in the treatment of muscle-invasive bladder cancer. 2017 , 14, 565-574	65
2156	A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. 2017 , 44, 136-140	119
2155	mUC: Mehr Lebensqualität durch PD-1-Inhibitor in der Zweitlinie. 2017 , 20, 30-30	
2154	PD-L1 blockade for urothelial carcinoma. 2017 , 6, e1334028	5

2153	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. 2017 , 15, 150	22
2152	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials. 2017 , 96, e8931	17
2151	Immunotherapy in the Elderly. 2017 , 3, 403-412	12
2150	Systemische Behandlung des Harnblasenkarzinoms. 2017 , 20, 50-58	
2149	Survival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. 2017 , 3, 121-132	19
2148	Current management of advanced bladder cancer. 2017 , 8, 8-12	3
2147	New research in bladder cancer, ASCO 2017. 2017 , 11, S301-2	
2146	Clinical use of immune checkpoint inhibitors. 2017 ,	
2145	Chemotherapie des Harnblasenkarzinoms. 2017 , 38, 368-372	
2144	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. 2017 , 8, 730	233
2143	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. 2017 , 13, 1259-1271	12
2142	Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. 2017 , 10, 2097-2106	32
2141	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. 2017 , 6, 51-71	76
2140	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. 2017 , 18,	60
2139	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. 2017 , 8, 1597	145
2138	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. 2017 , 8, 1547	80
2137	A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma. 2017 , 2017, 6940546	25
2136	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. 2017 , 2017, 5618174	8

2135	Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. 2017 ,	1
2134	Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?. 2017 , 6, 1067-1080	13
2133	Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway. 2017 , 13,	
2132	Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future. 2017 , 84, 130-141	7
2131	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. 2017 , 5, 68	48
2130	Biomarkers for immunotherapy in bladder cancer: a moving target. 2017 , 5, 94	100
2129	mUC: mehr Lebensqualität durch PD-1-Inhibitor in der Zweitlinie. 2017 , 21, 58-58	
2128	PD1-Antikörper verlängert Überleben bei fortgeschrittenem Urothelkarzinom. 2017 , 20, 36-37	
2127	PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. 2017 , 8, 66849-66864	38
2126	Immune Checkpoint Blockade in Metastatic Urothelial Cancer. 2017 , 35, 2109-2112	9
2125	Evolving Treatment of Advanced Urothelial Cancer. 2017 , 13, 309-315	16
2124	Bending the Curve of Advanced Urothelial Carcinoma. 2017 , 13, 319-320	
2123	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. 2017 , 1, 132-142	2
2122	Current markers and their value in the era of immuno-oncology. 2017 , 6, 1111-1116	5
2121	Different stages in drug development for muscle-invasive bladder cancer. 2017 , 6, 1060-1066	2
2120	Oncogenic pathways as the basis of primary immune ignorance. 2017 , 1, 421-428	
2119	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. 2018 , 73, 800-806	16
2118	Novel biomarkers in bladder cancer. 2018 , 36, 115-119	4

2117	Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?. 2018 , 6, 250-254	3
2116	An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. 2018 , 10,	28
2115	Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer. 2018 , 29, 1320-1324	21
2114	Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. 2018 , 23, 410-420	40
2113	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. 2018 , 124, 2115-2124	51
2112	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. 2018 , 19, 16	5
2111	Durvalumab in urothelial cancers. 2018 , 18, 311-318	6
2110	Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. 2018 , 36, 423-431	7
2109	The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis. 2018 , 59, 328-338	11
2108	Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?. 2018 , 74, 63-65	3
2107	Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. 2018 , 24, 1-5	7
2106	[Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors : Immune-mediated side effects]. 2018 , 57, 543-551	3
2105	PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer. 2018 , 11, 43-46	19
2104	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. 2018 , 13, 353-361	11
2103	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. 2018 , 36, 405-412	30
2102	Cost considerations for systemic therapy for patients with advanced genitourinary malignancies. 2018 , 124, 2897-2905	4
2101	[Advanced bladder cancer : From chemo- to immunotherapy]. 2018 , 57, 686-692	
2100	Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. 2018 , 20, 48	29

2099	Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma. 2018 , 45, 287-295	8
2098	Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. 2018 , 199, 1129-1142	28
2097	Recent developments in the treatment of advanced bladder cancer. 2018 , 36, 109-114	25
2096	The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment. 2018 , 28, 43-50	11
2095	Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer. 2018 , 118, 57-61	31
2094	TGFβ ₁ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. 2018 , 554, 544-548	1697
2093	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. 2018 , 13, 1-20	23
2092	Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy. 2018 , 18, 377-387	4
2091	Targeting bladder cancer using activated T cells armed with bispecific antibodies. 2018 , 39, 1245-1252	5
2090	Immune checkpoint inhibitors for metastatic bladder cancer. 2018 , 64, 11-20	57
2089	Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. 2018 , 4, 537-544	82
2088	Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). 2018 , 143, 45-51	52
2087	Hypermutated Tumors and Immune Checkpoint Inhibition. 2018 , 78, 155-162	16
2086	Checkpoint Inhibitors, Palliative Care, or Hospice. 2018 , 20, 2	8
2085	M7824, a novel bifunctional anti-PD-L1/TGFβ ₁ trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. 2018 , 7, e1426519	109
2084	Role of immunotherapy in bladder cancer: past, present and future. 2018 , 81, 629-645	26
2083	Nivolumab for the treatment of urothelial cancers. 2018 , 18, 215-221	14
2082	Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond. 2018 , 24, 20-30	14

2081	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. 2018 , 73, 462-468	23
2080	T cell exhaustion in cancer: Mechanisms and clinical implications. 2018 , 119, 4279-4286	20
2079	Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. 2018 , 10, 85-91	25
2078	Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review. 2018 , 10, 139-148	10
2077	Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio. 2018 , 16, e637-e644	3
2076	Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. 2018 , 4, 326-332	36
2075	Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer. 2018 , 16, 235-239	3
2074	A critical review on ramucirumab in the treatment of advanced urothelial cancer. 2018 , 14, 1049-1061	4
2073	Pembrolizumab for the treatment of bladder cancer. 2018 , 18, 107-114	9
2072	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. 2018 , 391, 748-757	753
2071	BCG and Anti-PDL-1 Ab in Bladder Cancers. 2018 , 357-369	
2070	Atezolizumab for platinum-treated metastatic urothelial carcinoma. 2018 , 391, 716-718	9
2069	Reply to Georgios Papadopoulos, Charalampos Fragkoulis, and Konstantinos Ntoumas' Letter to the Editor re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. <i>Eur Urol</i> 2017;72:660-4. 2018 , 73, e53	
2068	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. 2018 , 73, 751-759	67
2067	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. 2018 , 52, 241-252	9
2066	Inhibitors of the PD-1 Pathway in Tumor Therapy. 2018 , 200, 375-383	82
2065	Molecular Biomarkers in the Clinical Management of Prostate Cancer. 2018 , 8,	10
2064	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. 2018 , 30, 13-22	53

2063	Integration of radiation and immunotherapy in breast cancer - Treatment implications. 2018 , 38, 66-74	26
2062	The Basics of Cancer Immunotherapy. 2018 ,	2
2061	Genitourinary Malignancies. 2018 , 79-94	
2060	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. 2018 , 360, k793	262
2059	Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. 2018 , 18, 395	12
2058	PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. 2018 , 13, 5	15
2057	SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. 2018 , 19, 216	6
2056	Aktuelle Systemtherapie des metastasierten Harnblasenkarzinoms. 2018 , 13, 140-147	
2055	Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes. 2018 , 11, 3-4	
2054	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. 2018 , 16, e961-e967	12
2053	Expression Differentiation Is Not Helpful in Identifying Prognostic Genes Based on TCGA Datasets. 2018 , 11, 292-299	7
2052	Treatment resistance in urothelial carcinoma: an evolutionary perspective. 2018 , 15, 495-509	26
2051	The binding of an anti-PD-1 antibody to Fc γ R1 has a profound impact on its biological functions. 2018 , 67, 1079-1090	71
2050	Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer. 2018 , 7, e1448332	34
2049	CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. 2018 , 38, 1063-1078	164
2048	CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. 2018 , 1, e1002	3
2047	Liquid Biopsies and Cancer Immunotherapy. 2018 , 24, 78-83	12
2046	Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis. 2018 , 97, e9617	37

2045	Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area. 2018 , 34, 1059-1068	62
2044	Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake. 2018 , 10, 423-425	1
2043	[The role of biomarkers in the diagnosis, prognosis and therapy of patients with immuno-oncological treatments of genito-urinary carcinomas]. 2018 , 49, 171-177	
2042	[Immune checkpoint inhibition in metastatic urothelial carcinoma]. 2018 , 49, 178-186	1
2041	[Immunotherapy with checkpoint inhibitors in local advanced and metastatic urothelial carcinoma]. 2018 , 49, 142-156	2
2040	Regulation and Function of the PD-L1 Checkpoint. 2018 , 48, 434-452	783
2039	Recent advances in medical therapy for metastatic urothelial cancer. 2018 , 23, 599-607	15
2038	Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. 2018 , 16, e751-e760	9
2037	The emerging role of immunotherapy in advanced urothelial cancers. 2018 , 30, 172-180	5
2036	Cancer immunotherapy using checkpoint blockade. 2018 , 359, 1350-1355	2480
2035	A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer. 2018 , 10, 657-663	10
2034	Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. 2018 , 94, 179-186	53
2033	[Systemic immune checkpoint inhibition : A promising treatment for urological tumors?]. 2018 , 57, 583-590	1
2032	Avelumab for the treatment of urothelial cancer. 2018 , 18, 421-429	6
2031	The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. 2018 , 36, 459-468	8
2030	The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. 2018 , 8,	8
2029	Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. 2018 , 29, 209-214	98
2028	The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer. 2018 , 15, 251-259	15

2027	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. 2018 , 4, 442-454	6
2026	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. 2018 , 29, 71-83	154
2025	Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum. 2018 , 73, 153-155	
2024	Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. 2018 , 16, e373-e382	2
2023	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. 2017 ,	5
2022	Immunotherapy for metastatic urothelial carcinoma: status quo and the future. 2018 , 28, 1-7	5
2021	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. 2018 , 52, 216-227	11
2020	Survival outcomes for patients with localised upper tract urothelial carcinoma managed with non-definitive treatment. 2018 , 121, 124-129	4
2019	The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. 2018 , 7, e1386362	39
2018	The application and mechanism of PD pathway blockade for cancer therapy. 2018 , 94, 53-60	9
2017	The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma. 2018 , 52, 60-68	5
2016	Role of Immunotherapy in Head and Neck Cancer. 2018 , 28, 12-16	47
2015	Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia. 2018 , 453, 44-52	11
2014	Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer. 2018 , 112, 225.e1-225.e7	10
2013	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. 2018 , 27, 55-70	3
2012	Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. 2018 , 16, 117-129	21
2011	Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma. 2018 , 15, 73-74	2
2010	Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. 2018 , 15, 92-111	84

2009	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. 2018 , 15, 112-124	52
2008	Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade. 2018 , 15, 71-72	7
2007	Immunotherapeutic Biomarkers and Selection Strategies. 2018 , 69-114	
2006	Why overall survival and not progression free survival improves in era of program death inhibitors. 2018 , 24, 398-399	0
2005	The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. 2018 , 73, 543-557	66
2004	Hepatocellular carcinoma in the era of immunotherapy. 2018 , 42, 40-48	71
2003	Reply to Nelson Martinez Merizalde Balarezo, Mark Monroe Rivera, and Romina A. Tejada's Letter to the Editor re: Maud Rijnders, Ronald de Wit, Joost L. Boormans, Martijn P.J. Lolkema, Astrid A.M. van der Veldt. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. <i>Eur Urol</i> . 2017;72:411-23. Beyond the Survival Rate, Health-related Quality of Life is Important. 2018 , 73, e67-e68	
2002	High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. 2018 , 67, 403-412	39
2001	Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. 2018 , 36, 413-422	16
2000	Biomarkers for immunotherapy in urological cancers. 2018 , 28, 25-28	1
1999	Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research. 2018 , 38, 400-414	37
1998	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. 2018 , 36, 1020-1044	83
1997	Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. 2018 , 38, 342-353	6
1996	[Immunotherapy and bladder cancer]. 2018 , 212, 81-84	2
1995	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. 2018 , 36, 1685-1694	274
1994	Patterns of Response and Progression to Immunotherapy. 2018 , 38, 169-178	128
1993	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. 2018 , 36, 3353-3360	265
1992	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. 2018 , 36, 1579-1587	68

1991 Reply to S. Zhang et al. **2018**, 36, 3057-3058

1990 The Effort in Exploration of a Definitive Predictive Factor From PD-1/PD-L1 Blockade in Advanced or Metastatic Urothelial Cancer. **2018**, 36, 3056-3057 2

1989 Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?. **2018**, 7, S198-S201 3

1988 Hematological adverse events related to the immune system with immune checkpoint inhibitors, a comprehensive review as a basis for clinical guidelines. **2018**, 24, 183-193

1987 Systemic transduction of p16 antitumor peptide inhibits lung metastasis of the MBT-2 bladder tumor cell line in mice. **2019**, 17, 1203-1210 1

1986 Immunotherapie dans les carcinomes urothéliaux. **2018**, 105 Suppl 1, S43-S49

1985 The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages. **2018**, 9, 7942-7948 18

1984 French ccAFU guidelines Update 2018-2020: Bladder cancer. **2019**, 28, R48-R80 5

1983 A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. **2018**, 9, 15001-15014 22

1982 Beim richtigen Patienten zur richtigen Zeit das richtige Medikament. **2018**, 22, 28-32

1981 Urothelkarzinom der Harnblase: Aktuelles zur Systemtherapie. **2018**, 21, 46-54

1980 [Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs]. **2018**, 105, 1202-1208 1

1979 Die Rolle von Biomarkern bei Diagnose, Prognose und Therapie von Patienten unter immunonkologischer Therapie mit urologischen Malignomen. **2018**, 39, 671-677

1978 Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. **2018**, 19, 109 32

1977 Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. **2018**, 363, k4226 191

1976 Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. **2018**, 10, 1303-1313 1

1975 Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis. **2018**, 11, 7529-7542 20

1974 Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer. **2018**, 28, 479-484 4

1973	A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. 2018 , 6, 128	138
1972	[Urology - what are the most important trends over the last decade?]. 2018 , 160, 99-102	
1971	Combination of PD-1 blockade and RetroNectin-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. 2018 , 10, 1315-1323	3
1970	Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma. 2018 , 4, FSO341	6
1969	PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer. 2018 , 18, 97	24
1968	Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. 2018 , 7, e1500108	34
1967	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018. 2018 , 6, 114	29
1966	Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. 2018 , 25, e373-e384	61
1965	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. 2018 , 19, 70	12
1964	The promise of immunotherapy in genitourinary malignancies. 2018 , 1, 97-101	2
1963	The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis. 2018 , 9, 1430	54
1962	Immunotherapy Advances in Urothelial Carcinoma. 2018 , 19, 79	3
1961	The continuing role of chemotherapy in the management of advanced urothelial cancer. 2018 , 10, 455-480	11
1960	Long-term Survival After Treating Cardiac Metastasis With Radiation and Immune Therapy: A Case Report. 2018 , 10, e2607	5
1959	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. 2018 , 7,	38
1958	Prime time for immunotherapy in advanced urothelial cancer. 2018 , 14 Suppl 5, 24-32	2
1957	Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. 2018 , 215, 2748-2759	19
1956	From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. 2018 , 1, 486-500	19

1955	The intracellular signalosome of PD-L1 in cancer cells. 2018 , 3, 26	108
1954	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. 2018 , 13, 599-609	12
1953	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. 2018 , 17, 2746-2755	34
1952	PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. 2018 , 11, 5973-5989	59
1951	Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues. 2018 , 17, 3932-3940	8
1950	Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis. 2018 , 10, 3669-3677	2
1949	Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen. 2018 , 104, 236-238	5
1948	Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer. 2018 , 11, 88	3
1947	[Immunotherapy for locally advanced and metastasized bladder cancer]. 2018 , 57, 1334-1341	1
1946	Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy. 2018 , 19, 108	12
1945	Role of noninvasive molecular imaging in determining response. 2018 , 3, 534-547	17
1944	A Festschrift in Honor of Edward M. Messing, MD, FACS. 2018 , 4, S1-S43	
1943	[Mode of action, new targets and potential biomarkers in modern immunotherapy]. 2018 , 57, 1301-1308	1
1942	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. 2018 , 104, 137-144	63
1941	RETRACTED: Recommandations françaises du Comité de Cancérologie de l'AFU [Actualisation 2018-2020 : tumeurs de la vessie French ccAFU guidelines [Update 2018-2020: Bladder cancer. 2018 , 28, S46-S78	11
1940	Hyperprogressive disease: recognizing a novel pattern to improve patient management. 2018 , 15, 748-762	206
1939	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 T cells in the tumor microenvironment. 2018 , 6, 106	85
1938	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. 2018 , 6, 103	89

1937	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. 2018 , 9, 8706-8715	52
1936	Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy. 2018 , 11, 6525-6537	9
1935	Precision medicine and bladder cancer heterogeneity. 2018 , 105, 925-931	15
1934	The latest treatment options for bladder cancer. 2018 , 128, 85-95	17
1933	TIM-3 expression in breast cancer. 2018 , 7, e1502128	34
1932	Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. 2018 , 11, 877-891	
1931	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. 2018 , 119, 707-712	18
1930	Immune checkpoint inhibitors for urothelial carcinoma. 2018 , 59, 285-296	55
1929	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. 2018 , 103, 7-16	32
1928	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. 2018 , 200, 1207-1214	10
1927	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. 2018 , 16, 1041-1053	128
1926	TIGIT: a novel immunotherapy target moving from bench to bedside. 2018 , 67, 1659-1667	107
1925	Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer. 2018 , 19,	9
1924	Long-term survival of a patient with pulmonary metastatic urothelial carcinoma following metastasectomy. 2018 , 21, 52-55	
1923	Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. 2018 , 362, k3529	205
1922	Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK. 2018 , 5, MMT05	18
1921	RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. 2018 , 473, 719-724	19
1920	Profiling targetable immune checkpoints in osteosarcoma. 2018 , 7, e1475873	19

1919	Prognostic and predictive models in hormone-sensitive prostate cancer. 2018 , 122, 352-353	1
1918	A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany. 2018 , 9, 1337-1348	27
1917	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. 2018 , 29, 2175-2182	13
1916	Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study. 2018 , 16, 421-428.e1	7
1915	Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring. 2018 , 19,	47
1914	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. 2018 , 9, 3503	124
1913	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. 2018 , 12, 209-215	20
1912	Current Role of Checkpoint Inhibitors in Urologic Cancers. 2018 , 175, 241-258	5
1911	The Cancer Genome Atlas Project in Bladder Cancer. 2018 , 175, 259-271	11
1910	Immune checkpoint inhibitors and cardiovascular toxicity. 2018 , 19, e447-e458	221
1909	Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8. 2018 , 74, e12-e13	
1908	Does a patient's sex predict the efficacy of cancer immunotherapy?. 2018 , 19, 716-717	18
1907	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). 2018 , 118, 1434-1441	17
1906	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. 2018 , 39, 624-631	101
1905	Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy. 2018 , 78, 3954-3968	47
1904	Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma. 2018 , 23, 944-950	6
1903	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. 2018 , 56, 460-472	13
1902	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. 2018 , 430, 2014-2029	30

1901	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. 2018 , 23, 1171-1177	19
1900	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. 2018 , 36, 1727-1740	54
1899	Therapeutic strategies for upper tract urothelial carcinoma. 2018 , 18, 765-774	8
1898	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with Alterations. 2018 , 8, 812-821	145
1897	Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. 2018 , 19, 737-746	353
1896	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. 2018 , 37, 4639-4661	133
1895	Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer. 2018 , 67, 1371-1380	11
1894	Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan. 2018 , 48, 771-776	13
1893	Seeking Convergence and Cure with New Myeloma Therapies. 2018 , 4, 567-582	5
1892	Molecularly-driven precision medicine for advanced bladder cancer. 2018 , 36, 1749-1757	3
1891	Role of Checkpoint Inhibition in Localized Bladder Cancer. 2018 , 1, 190-198	17
1890	PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases. 2018 , 81, 184-191	12
1889	Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases. 2018 , 31, 1869-1881	22
1888	A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes. 2018 , 1, e180416	30
1887	Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. 2018 , 6, 40	76
1886	A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. 2018 , 29, e81	6
1885	Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. 2018 , 12, 1645-1657	13
1884	Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer. 2018 , 4, 429-440	5

1883	Sex as a predictor of response to cancer immunotherapy. 2018 , 19, e379	3
1882	7 - Terapia Nella Malattia In Progressione E Metastatica. 2018 , 104, S27-S31	
1881	The Role of Urologist. 2018 , 101-112	
1880	Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. 2018 , 7, CD012838	4
1879	Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma. 2018 , 32, 2058738418790318	23
1878	Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. 2018 , 13, 47	24
1877	Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. 2018 , 14, 1019-1040	43
1876	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. 2018 , 74, 741-753	43
1875	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. 2018 , 15, 639-650	108
1874	The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count. 2018 , 7, 4330-4338	16
1873	Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4. 2018 , 6,	11
1872	Treating Urothelial Bladder Cancer. 2018 ,	
1871	Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy. 2018 , 9, 374	35
1870	Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. 2018 , 73, 983-989	16
1869	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. 2018 , 6, 46	86
1868	Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. 2018 , 10,	37
1867	Bladder Cancer: New Insights into Its Molecular Pathology. 2018 , 10,	52
1866	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. 2018 , 62, 29-39	496

1865	Update on the Treatment of Metastatic Urothelial Carcinoma. 2018 , 2018, 5682078	20
1864	Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States. 2018 , 4, 227-238	33
1863	Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. 2018 , 16, 903-908	9
1862	Novel therapies in urothelial carcinoma: a biomarker-driven approach. 2018 , 29, 2302-2312	4
1861	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). 2018 , 6, 63	165
1860	Mechanisms of BCG immunotherapy and its outlook for bladder cancer. 2018 , 15, 615-625	147
1859	Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. 2018 , 24, 6115-6124	10
1858	Hyperprogression as a distinct outcome after immunotherapy. 2018 , 70, 16-21	69
1857	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. 2018 , 19,	12
1856	Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma. 2018 , 15, 585-587	15
1855	Advances in the systemic treatment of triple-negative breast cancer. 2018 , 25, S142-S150	129
1854	Diagnostik und Therapie des Harnblasenkarzinoms. 2018 , 15, 9-20	
1853	Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. 2018 , 119, 538-545	73
1852	Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. 2018 , 6, 4	86
1851	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. 2018 , 6, 8	606
1850	Safety and efficacy of tamsirolimus as second line treatment for patients with recurrent bladder cancer. 2018 , 18, 194	10
1849	Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. 2018 , 6, 24	9
1848	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. 2018 , 7, R196-R211	9

1847	Treatment of Urothelial Cancer in Elderly Patients: Focus on Immune Checkpoint Inhibitors. 2018 , 35, 409-421	2
1846	Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma. 2018 , 35, 94	5
1845	Targeted Treatments for Common Solid Tumors. 2018 , 187-257	
1844	Therapeutic Vaccines for Genitourinary Malignancies. 2018 , 6,	7
1843	Antibody-Drug Conjugates in Bladder Cancer. 2018 , 4, 247-259	20
1842	A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. 2018 , 20, 894-904	25
1841	Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer. 2018 , 130, 36-43	0
1840	Immuntherapie mit Checkpoint-Inhibitoren beim lokal fortgeschrittenen und metastasierten Urothelzellkarzinom. 2018 , 39, 307-320	
1839	Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies. 2018 , 4, 149-159	19
1838	Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer. 2018 , 5,	34
1837	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. 2018 , 129, 124-132	11
1836	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. 2018 , 144, 2245-2261	16
1835	CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. 2018 , 35, 233-243	60
1834	Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease. 2018 , 10, 7-16	20
1833	Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment. 2018 , 9, 1614-1622	12
1832	EMA and FDA prune the checkpoint inhibitor treatment landscape. 2018 , 15, 596-597	5
1831	Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. 2018 , 17, 995-1003	17
1830	Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. 2018 , 10, 1758835918788310	10

1829	The Association of Aspirin Use with Survival Following Radical Cystectomy. 2018 , 200, 1014-1021	9
1828	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. 2018 , 10, 2475-2488	11
1827	Patient performance status and cancer immunotherapy efficacy: a meta-analysis. 2018 , 35, 132	32
1826	Expert opinion on thyroid complications in immunotherapy. 2018 , 79, 555-561	21
1825	PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab. 2018 , 7, e1460298	10
1824	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. 2018 , 392, 123-133	624
1823	Advances in medical treatments for genitourinary cancers. 2018 , 29, 155-162	
1822	Clinical Features and Risk Factors of Skeletal-Related Events in Genitourinary Cancer Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma. 2018 , 95, 170-178	11
1821	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. 2018 , 68, 80-85	18
1820	Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients. 2018 , 16, e1015-e1024	7
1819	Immunotherapy and next-generation sequencing guided therapy for precision oncology: What have we learnt and what does the future hold?. 2018 , 3, 205-213	2
1818	Recent progress in therapeutic antibodies for cancer immunotherapy. 2018 , 44, 56-65	19
1817	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. 2019 , 105, 582-597	7
1816	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. 2019 , 29, 29-39	29
1815	Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. 2019 , 143, 330-337	237
1814	Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. 2019 , 34, 108-117	85
1813	Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience. 2019 , 113, 50-60	5
1812	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. 2019 , 74, 49-60	16

1811	Rash and Pruritus With PD-1 Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials. 2019 , 59, 45-54	0
1810	Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. 2019 , 37, 19-27	6
1809	#Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?. 2019 , 123, 203-207	2
1808	Modulating T-cell-based cancer immunotherapy via particulate systems. 2019 , 27, 145-163	7
1807	Contrast-Induced Acute Kidney Injury Among Patients With Chronic Kidney Disease Undergoing Imaging Studies: A Meta-Analysis. 2019 , 213, 728-735	10
1806	DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade. 2019 , 10, 724	8
1805	Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. 2019 , 24 Suppl 2, S74-S85	27
1804	Special Issue on Molecular Research Efforts in Urothelial Carcinoma: Summary of Included Topics. 2019 , 20,	1
1803	Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. 2019 , 11, 521-534	12
1802	Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer. 2019 , 12, 1416-1424	7
1801	Current advances in BCG-unresponsive non-muscle invasive bladder cancer. 2019 , 28, 757-770	12
1800	Neue Therapieoptionen Und Probleme. 2019 , 23, 14-18	
1799	The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. 2019 , 19, 407-416	7
1798	Management of Urothelial Bladder Cancer in Clinical Practice: Real-World Answers to Difficult Questions. 2019 , 15, 421-428	16
1797	Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer. 2019 , 58, 951-952	
1796	Predictive biomarkers for drug response in bladder cancer. 2019 , 26, 1044-1053	28
1795	Which place for avelumab in the management of urothelial carcinoma?. 2019 , 19, 863-870	3
1794	Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?. 2019 , 15, 1505-1524	10

1793	Second-Line Systemic Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase Clinical Trials. 2019 , 9, 679	2
1792	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients. 2019 , 121, 230-236	8
1791	Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases. 2019 , 12, 5293-5298	15
1790	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. 2019 , 5, 1195-1204	224
1789	Pembrolizumab for the treatment of cervical cancer. 2019 , 19, 871-877	7
1788	MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance. 2019 , 2019, 7346492	15
1787	[50 years of systemic therapy of urinary bladder cancer]. 2019 , 50, 358-365	2
1786	Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs. 2019 , 20,	7
1785	Molecular and histopathology directed therapy for advanced bladder cancer. 2019 , 16, 465-483	73
1784	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. 2019 , 20, 1109-1123	113
1783	Pembrolizumab for the treatment of head and neck squamous cell cancer. 2019 , 19, 879-885	4
1782	Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer. 2019 , 36, 927-938	45
1781	Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma. 2019 , 29, 1269-1278	11
1780	Macrophage-Mediated Subversion of Anti-Tumour Immunity. 2019 , 8,	43
1779	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2019 , 381, 338-348	59.2 456
1778	Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. 2019 , 37, 2592-2600	226
1777	Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer. 2019 , 5, 131-145	3
1776	The Role of Myeloid Derived Suppressor Cells in Urothelial Carcinoma Immunotherapy. 2019 , 5, 103-114	1

1775	Advanced urothelial cancer: a radiology update. 2019 , 44, 3858-3873	3
1774	Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer. 2019 , 76, 604-606	2
1773	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. 2019 , 37, 573.e19-573.e29	3
1772	Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy. 2019 , 20, 67	10
1771	Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials?. 2019 , 37, 2587-2591	4
1770	Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. 2019 , 25, 1073-1081	71
1769	Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer. 2019 , 39, 3887-3892	14
1768	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. 2019 , 28, 369-386	13
1767	Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. 2019 , 8, 4644-4655	35
1766	Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. 2019 , 475, 599-608	27
1765	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. 2019 , 7, 267	63
1764	Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. 2019 , 4, e000531	34
1763	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. 2019 , 145, 3021-3036	11
1762	Erdafitinib in Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1593-1594	59.2 3
1761	Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma. 2019 , 5, 170-177	2
1760	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. 2019 , 11, 1758835919875549	10
1759	Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA. 2019 , 15, 3809-3818	4
1758	Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. 2019 , 9, 972	11

1757	Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. 2019 , 14, 99	24
1756	The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. 2019 , 10, 1063	2
1755	Road map to best practices. 2019 , 241-273	0
1754	Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer: Time to Change Clinical Practice?. 2019 , 37, 939	2
1753	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. 2019 , 144, 102812	5
1752	Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. 2019 , 18, 155	353
1751	Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. 2019 , 11,	54
1750	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. 2019 , 20,	33
1749	Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. 2019 , 8, 7503-7515	17
1748	New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?. 2019 , 7, S135	11
1747	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. 2019 , 394, 1915-1928	839
1746	Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer. 2019 , 25, 1650-1651	5
1745	A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer. 2019 , 9, 1066	30
1744	Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies. 2019 , 121, 1027-1038	18
1743	Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis. 2019 , 15, 3633-3646	4
1742	[Influence of immunomodulators on urological imaging]. 2019 , 58, 1451-1460	
1741	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. 2019 , 8,	22
1740	Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?. 2019 , 122, 72-90	53

1739	The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. 2019 , 7, 278	281
1738	Advanced/metastatic urothelial carcinoma of the bladder and upper urinary tract. 2019 , 12, 324-328	0
1737	Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. 2019 , 94, 58-63	3
1736	Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet. 2019 , 10, 1125	17
1735	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. 2019 , 11,	11
1734	Toll-like receptors: The role in bladder cancer development, progression and immunotherapy. 2019 , 90, e12818	28
1733	Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy. 2019 , 12, 548-553	1
1732	Genomics and Therapeutic Decisions in Urothelial Malignancies. 2019 , 15, 431-432	
1731	Integrin-Mediated TGF β Activation Modulates the Tumour Microenvironment. 2019 , 11,	38
1730	The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis. 2019 , 8, 5969-5978	17
1729	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. 2019 , 9, 25	26
1728	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. 2019 , 19, 857	46
1727	Emerging therapeutic agents for genitourinary cancers. 2019 , 12, 89	22
1726	Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. 2019 , 155, 51-57	8
1725	Immunotherapy and urothelial carcinoma: An overview and future perspectives. 2019 , 143, 46-55	15
1724	The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis. 2019 , 9, 866	7
1723	The multifaceted immune regulation of bladder cancer. 2019 , 16, 613-630	58
1722	Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?. 2019 , 17, e1122-e1128	7

1721	Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. 2019 , 28, 821-826	10
1720	The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. 2019 , 12, 1756284819869767	16
1719	An update on immunotherapy options for urothelial cancer. 2019 , 19, 1265-1274	9
1718	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. 2019 , 20,	28
1717	Determining superior first-line therapy in metastatic bladder cancer. 2019 , 16, 698-699	1
1716	PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review. 2019 , 18, 505-510	21
1715	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. 2019 , 37, 826-836	15
1714	Pericardial effusion due to pembrolizumab-induced immunotoxicity: A case report and literature review. 2019 , 43, 504-510	10
1713	The Prognostic and Therapeutic Value of PD-L1 in Glioma. 2018 , 9, 1503	52
1712	The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). 2019 , 14, 15-32	5
1711	Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. 2019 , 46, 65-72	10
1710	Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. 2019 , 11, 429-441	29
1709	Prognostic value of programmed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. 2019 , 90, 30-37	27
1708	Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient's Bedside to Evaluation in Preclinical Models. 2019 , 11,	19
1707	Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. 2019 , 109, 21-27	121
1706	ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study. 2019 , 145, 765-774	17
1705	SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. 2019 , 37, 61-83	31
1704	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. 2019 , 11, 1756287218815372	6

1703	Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial. 2019 , 24, 745-e213	3
1702	Immunotherapy for genitourinary tumors. 2019 , 26, 326-333	6
1701	GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma. 2019 , 145, 1111-1124	26
1700	Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. 2019 , 50, 477-492.e8	56
1699	Epigenetic therapy in immune-oncology. 2019 , 19, 151-161	216
1698	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. 2019 , 75, 707-711	42
1697	Novel patterns of response under immunotherapy. 2019 , 30, 385-396	194
1696	Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. 2019 , 11, 4297-4312	28
1695	Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma. 2019 , 11, 4519-4528	6
1694	Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. 2019 , 11, 4171-4184	19
1693	Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer. 2019 , 5, 87-102	5
1692	Impact of histologic variants on the oncological outcomes of patients with upper urinary tract cancers treated with radical surgery: a multi-institutional retrospective study. 2019 , 24, 1412-1418	1
1691	Recent advances in the clinical development of immune checkpoint blockade therapy. 2019 , 42, 609-626	38
1690	Impact of Neoadjuvant Chemotherapy on Concordance of PD-L1 Staining Fidelity between the Primary Tumor and Lymph Node Metastases in Bladder Cancer. 2019 , 131, 150-156	6
1689	Immunohistochemistry-Enabled Precision Medicine. 2019 , 178, 111-135	4
1688	Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma. 2019 , 49, 965-971	3
1687	A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. 2019 , 32, 1646-1656	11
1686	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. 2019 , 76, 368-380	26

1685	Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3K β Inhibitor TAK-117 in Preclinical Bladder Cancer Models. 2019 , 17, 1931-1944	12
1684	[Molecular tumor board-urothelial cancer]. 2019 , 58, 760-767	
1683	Hyperprogression during immunotherapy: do we really want to know?. 2019 , 30, 1028-1031	11
1682	DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes. 2019 , 7, 148	32
1681	Consultation on UTUC, Stockholm 2018: aspects of treatment. 2019 , 37, 2279-2287	6
1680	Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series. 2019 , 140, 80-87	2
1679	Application of PD-1 Blockade in Cancer Immunotherapy. 2019 , 17, 661-674	184
1678	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. 2019 , 66, 1-8	14
1677	High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer. 2019 , 11, 2987-2995	17
1676	Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. 2019 , 2019, 2532518	7
1675	Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology. 2019 , 17, e888-e892	3
1674	Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?. 2019 , 8, S91-S92	
1673	PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes. 2019 , 152, 384-391	4
1672	Patient-derived bladder cancer xenograft models reveal VEGF and CDK4 enhancing tumor metastasis behavior.. 2019 , 9, 17877-17884	1
1671	Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. 2019 , 141, 23-35	26
1670	Hyperprogression under Immunotherapy. 2019 , 20,	63
1669	Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12. 2019 , 7, 150	11
1668	Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. 2019 , 76, 782-789	22

1667	Organ preservation in bladder cancer: an opportunity for truly personalized treatment. 2019 , 16, 511-522	22
1666	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. 2019 , 38, 255	296
1665	Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. 2019 , 14, e0217276	16
1664	Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. 2019 , 37, 2730-2737	124
1663	Immune checkpoint inhibitors in malignancy. 2019 , 42, 62-67	17
1662	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. 2019 , 318-327	5
1661	Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. 2019 , 39, 284-300	9
1660	Immunotherapy in Older Adults: A Checkpoint to Palliation?. 2019 , 39, e110-e120	8
1659	A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder. 2019 , 17, e672-e677	2
1658	Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival. 2019 , 37, 791-799	15
1657	Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. 2019 , 19, 517-529	8
1656	PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. 2019 , 76, 51-56	22
1655	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. 2019 , 8, e1581556	40
1654	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. 2019 , 25, 4808-4819	42
1653	[Predictive biomarkers in oncologic uropathology]. 2019 , 40, 264-275	1
1652	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. 2019 , 39, 147-164	248
1651	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. 2019 , 37, 1608-1616	108
1650	Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. 2019 , 249, 151-165	35

1649	Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities. 2019 , 16, 433-445	18
1648	Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience. 2019 , 11, 1756287219839285	7
1647	The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination. 2019 , 11, S347-S351	5
1646	Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma. 2019 , 20,	10
1645	Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis. 2019 , 26, e260-e265	2
1644	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. 2019 , 76, 22-32	131
1643	Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. 2019 , 37, 810.e7-810.e15	15
1642	Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. 2019 , 30, 970-976	158
1641	Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. 2019 , 10, 2025	231
1640	Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential. 2019 , 12, 2505-2512	10
1639	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. 2019 , 2, e193433	8
1638	Landmark Trials in Oncology. 2019 ,	
1637	Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. 2019 , 5, 887-892	43
1636	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. 2019 , 5, 1008-1019	288
1635	Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. 2019 , 202, 3458-3467	23
1634	Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up. 2019 , 106, 810-820	18
1633	Reply to S. Zhang. 2019 , 37, 940-941	
1632	Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors. 2019 ,	1

1631	IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. 2019 , 7, 860-865	40
1630	Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence. 2019 , 37, 1863-1867	51
1629	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. 2019 , 143, 63-144	26
1628	Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder. 2019 , 89, 24-32	9
1627	Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. 2019 , 7, 82	45
1626	A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer. 2019 , 12, 1791-1801	11
1625	The interplay among psychological distress, the immune system, and brain tumor patient outcomes. 2019 , 28, 44-50	11
1624	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. 2019 , 76, 73-81	74
1623	Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review. 2019 , 58, 137-156.e1	25
1622	Precision therapy in advanced urothelial cancer. 2019 , 4, 81-93	2
1621	Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. 2019 , 2, 12-20	8
1620	Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. 2019 , 6, 402-409	26
1619	Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase. 2019 , 12, 669-682	10
1618	Urothelkarzinom: Zweitlinientherapie mit Pembrolizumab verlängert Überlebenszeit. 2019 , 50, 14-16	
1617	Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience. 2019 , 19, 100124	4
1616	Systematic Review: Targeting HER2 in Bladder Cancer. 2019 , 5, 1-12	22
1615	Diabetes mellitus secondary to treatment with immune checkpoint inhibitors. 2019 , 26, e111-e114	14
1614	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. 2019 , 51, 145-156	130

1613	Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma. 2019 , 22, 662-670	11
1612	Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. 2019 , 30, 1104-1113	120
1611	Management of metastatic bladder cancer. 2019 , 76, 10-21	104
1610	Treatment of Metastatic Urothelial Cancer in 2018. 2019 , 5, 904-905	2
1609	Hyperprogression after pembrolizumab treatment in two patients with metastatic urothelial carcinoma. 2019 , 49, 473-476	5
1608	Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors. 2019 , 10, 407	32
1607	Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. 2019 , 17, e602-e611	9
1606	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. 2019 , 393, 1819-1830	1272
1605	Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice. 2019 , 24, e397-e399	17
1604	CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer. 2019 , 38, 90	20
1603	New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment. 2019 , 38, 91	38
1602	Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer. 2019 , 10, 697-707	7
1601	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. 2019 , 37, 1198-1206	8
1600	Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. <i>Eur Urol</i> 2019;75:538-40. 2019 , 75, e160-e161	
1599	Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer. 2019 , 11, 1756287218823678	6
1598	Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review. 2019 , 135, 76-84	5
1597	Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer. 2019 , 20, 12	10
1596	Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. 2019 , 17, 177-182	8

1595	A review of avelumab in locally advanced and metastatic bladder cancer. 2019 , 11, 1756287218823485	13
1594	Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). 2019 , 7, 46	6
1593	Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. 2019 , 21, 24	13
1592	A Rare Case of Advanced Urethral Diverticular Adenocarcinoma and a Review of Treatment Modalities. 2019 , 7, 2324709619828408	2
1591	PD-L1 Expression Reveals Significant Association With Squamous Differentiation in Upper Tract Urothelial Carcinoma. 2019 , 151, 561-573	9
1590	MCL1 and DEDD Promote Urothelial Carcinoma Progression. 2019 , 17, 1294-1304	2
1589	Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. 2019 , 10, 108	68
1588	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. 2019 , 58, 1-8	14
1587	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. 2019 , 474, 421-432	28
1586	[Immunotherapy in urology: Concept and results]. 2019 , 29, 922-928	
1585	Systemtherapie des Harnblasenkarzinoms. 2019 , 40, 571-575	
1584	Second line immune checkpoint inhibition in urothelial cancer. 2019 , 8, 414-420	3
1583	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. 2019 , 24, 1469-1478	12
1582	[Personalised medicine in urothelial bladder cancer]. 2019 , 50, 502-508	0
1581	Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway. 2019 , 8, S469-S471	1
1580	Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials.. 2019 , 3, 1-10	22
1579	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. 2019 , 4, e000575	5
1578	EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees 2019 , 30, 1697-1727	28

1577	Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition. 2021 , 4, 659-662	2
1576	Immunotherapy and Radiation: Charting a Path Forward Together. 2019 , 33, 1057-1069	2
1575	Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. 2019 , 7, 306	300
1574	Immune checkpoint inhibitors win the 2018 Nobel Prize. 2019 , 42, 299-306	24
1573	[Care of advanced or metastatic bladder cancer in second line: A specific place for vinflunine]. 2019 , 106, 431-435	
1572	The impact of postoperative inflammatory biomarkers on oncologic outcomes of bladder cancer. 2019 , 29, 270-281	9
1571	Immunotherapy in Bladder Cancer. 2019 ,	14
1570	Nuclear Factor- κ B Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer. 2019 , 8,	1
1569	Advancements in the clinical management of upper tract urothelial carcinoma. 2019 , 19, 1051-1060	4
1568	Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors. 2019 , 20, 83	8
1567	Immune-Mediated Colitis. 2019 , 17, 506-523	2
1566	The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. 2019 , 9, 1161	58
1565	Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis. 2019 , 19, 125	4
1564	Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition. 2019 , 21, 108	30
1563	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. 2019 , 26, 96	19
1562	Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies: A Systematic Review and Meta-Analysis. 2019 , 42, 711-716	2
1561	PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis. 2019 , 5, 211-223	4
1560	A Review on the Pathogenesis and Clinical Management of Placental Site Trophoblastic Tumors. 2019 , 9, 937	7

1559	Evolving Concepts in the Evaluation and Management of Bladder Cancer in Elderly Men. 2019 , 8, 331-337	
1558	Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. 2019 , 32, 500-510	37
1557	The landscape of immunotherapy in metastatic urothelial carcinoma. 2019 , 29, 643-648	3
1556	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. 2019 , 28,	48
1555	A systematic analysis of immune genes and overall survival in cancer patients. 2019 , 19, 1225	17
1554	Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors: lessons learnt and perspectives. 2019 , 31, 439-444	3
1553	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies. 2019 , 43, 920-927	30
1552	Targeting advanced urothelial carcinoma-developing strategies. 2019 , 31, 207-215	10
1551	Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials. 2019 , 98, e15731	13
1550	Perioperative systemic therapy for bladder cancer. 2019 , 29, 220-226	4
1549	Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis. 2019 , 24, 75-83	19
1548	Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives. 2019 , 11, 659-672	2
1547	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). 2019 , 27, 699-714	23
1546	Intrinsic Molecular Subclassification of Urothelial Carcinoma of the Bladder: Are We Finally there?. 2019 , 26, 251-256	3
1545	Management of rheumatic complications of ICI therapy: a rheumatology viewpoint. 2019 , 58, vii49-vii58	15
1544	Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy. 2019 , 58, vii1-vii6	1
1543	miR-140-3p Suppresses Cell Growth And Induces Apoptosis In Colorectal Cancer By Targeting PD-L1. 2019 , 12, 10275-10285	23
1542	Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. 2019 , 2, 355-364	15

1541	Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence. 2019 , 18, 2185-2193	43
1540	Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. 2019 , 11, 17588359198900285	49
1539	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. 2019 , 24, 1013-1021	10
1538	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. 2019 , 24, 1348-1355	7
1537	[Optimizing the management of bladder cancer in older patients]. 2019 , 29, 849-864	0
1536	Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045"). 2019 , 8, 409-413	0
1535	The molecular limitations of biomarker research in bladder cancer. 2019 , 37, 837-848	16
1534	Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder. 2019 , 21, 280-288	2
1533	Immunotherapy for Prostate Cancer. 2019 , 9,	26
1532	Urologic Malignancies. 2019 , 115-133	
1531	Immune Checkpoint Inhibitors. 2019 , 1-17	1
1530	SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). 2019 , 21, 64-74	10
1529	Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation. 2019 , 17, 145-153.e5	10
1528	Refining existing knowledge and management of bladder cancer. 2019 , 16, 75-76	1
1527	Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis. 2019 , 5, 529-536	109
1526	The Cancer Immunogram: A Pledge for a Comprehensive Biomarker Approach for Personalized Immunotherapy in Urothelial Cancer. 2019 , 75, 445-447	7
1525	[Cochrane Rapid Review: the immune checkpoint inhibitor pembrolizumab versus chemotherapy for the treatment of advanced urothelial carcinoma]. 2019 , 58, 45-48	
1524	Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States. 2019 , 37, 180.e11-180.e18	6

1523	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. 2019 , 30, 44-56	784
1522	Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?. 2019 , 36, 1-11	5
1521	Product review: avelumab, an anti-PD-L1 antibody. 2019 , 15, 891-908	26
1520	Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism. 2019 , 68, 835-847	46
1519	Systemic treatments for metastatic urothelial carcinoma. 2019 , 20, 201-208	8
1518	Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. 2019 , 106, 1-11	16
1517	Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. 2019 , 30, 57-67	83
1516	Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. 2019 , 143, 722-731	11
1515	Treatment of Metastatic Bladder Cancer. 2019 , 123-137	
1514	Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. 2019 , 37, 299.e19-299.e25	19
1513	Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder. 2019 , 75, 354-364	3
1512	Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer. 2019 , 42, 66-72	4
1511	Management of Urothelial Carcinoma. 2019 ,	
1510	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. 2019 , 125, 533-540	26
1509	Effects of Variant Histology on the Oncologic Outcomes of Patients With Upper Urinary Tract Carcinoma After Radical Nephroureterectomy: A Propensity Score-Matched Analysis. 2019 , 17, e394-e407	5
1508	The clinical implication of gamma globulin levels in patients with nonmuscle-invasive bladder cancer. 2019 , 37, 291.e1-291.e7	3
1507	Radiotherapy and immunotherapy: a synergistic effect in cancer care. 2019 , 210, 47-53	25
1506	Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. 2019 , 15, 533-541	12

1505	Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients. 2019 , 96, 125-131	14
1504	Recent advances in upper tract urothelial carcinomas: From bench to clinics. 2019 , 26, 148-159	13
1503	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. 2019 , 37, 1773-1784	14
1502	Immunotherapeutic Approaches in Cancer. 2019 , 19-44	4
1501	Histone Deacetylase Inhibition Has Targeted Clinical Benefit in -Mutated Advanced Urothelial Carcinoma. 2019 , 18, 185-195	10
1500	Updates and novel treatments in urothelial carcinoma. 2019 , 25, 648-656	22
1499	Predictive Biomarkers and Targeted Therapies in Immuno-oncology. 2019 , 335-344	1
1498	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. 2019 , 106, 234-243	39
1497	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. 2019 , 123, 947-958	8
1496	Metal Drugs and the Anticancer Immune Response. 2019 , 119, 1519-1624	146
1495	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. 2019 , 393, 156-167	674
1494	PD-L1 Antibody Comparison in Urothelial Carcinoma. 2019 , 75, 538-540	26
1493	Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. 2019 , 37, 579-583	15
1492	Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells. 2019 , 120, 6347-6360	9
1491	CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of Status. 2019 , 25, 390-402	29
1490	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. 2019 , 37, 95-105	12
1489	Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients. 2019 , 18, e20-e38	37
1488	Molecular markers in bladder cancer. 2019 , 37, 31-40	58

1487	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. 2019 , 194, 84-106	154
1486	Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a Molecular Subtype Approach to Bladder Cancer is Also Needed. 2019 , 75, e37-e38	3
1485	The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. 2019 , 75, 435-444	54
1484	Post-translational modifications in bladder cancer: Expanding the tumor target repertoire. 2020 , 38, 858-866	8
1483	Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. 2020 , 3, 663-670	5
1482	Cardiovascular toxicities of therapy for genitourinary malignancies. 2020 , 38, 121-128	1
1481	Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis. 2020 , 11, 508-514	9
1480	The Role of PD-L1 Testing in Advanced Genitourinary Malignancies. 2020 , 6, 11-13	2
1479	First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report. 2020 , 26, 216-219	6
1478	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. 2020 , 3, 671-679	7
1477	Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. 2020 , 10, 723-733	38
1476	PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: and Abscopal Effects. 2020 , 19, 211-220	19
1475	The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. 2020 , 59, 96-100	5
1474	Genomic Medicine. 2020 ,	2
1473	Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma. 2020 , 107, 588-596	22
1472	Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. 2020 , 3, 680-686	7
1471	Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. 2020 , 25, 33-45	54
1470	Neoplasms of the Urinary Bladder. 2020 , 230-321.e19	1

1469	Carcinoma of the Bladder. 2020 , 1382-1400.e4	0
1468	First-line Immunotherapy in Metastatic Urothelial Carcinoma. 2020 , 6, 45-47	0
1467	A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma. 2020 , 38, 1056-1066	16
1466	Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors. 2020 , 26, 647-654	8
1465	Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC). 2020 , 38, 1517-1524	6
1464	Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors. 2020 , 18, e122-e133	16
1463	Adjuvant Therapy for Urothelial and Renal Cell Carcinoma. 2020 , 6, 3-6	1
1462	RNA Expression Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder Reveals a Basal-Like Molecular Subtype. 2020 , 190, 134-144	5
1461	Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16). 2020 , 127, 183-190	7
1460	Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. 2020 , 77, 269-276	24
1459	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. 2020 , 77, 439-446	119
1458	Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population. 2020 , 50, 80-88	11
1457	Targeting FGFR in bladder cancer: ready for clinical practice?. 2020 , 75, 49-56	3
1456	Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors. 2020 , 38, 105-106	13
1455	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. 2020 , 11, 41-50	1
1454	Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis. 2020 , 147, 116-127	28
1453	Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. 2020 , 31, 50-60	58
1452	Novel immunotherapy combinations for genitourinary cancers. 2020 , 20, 253-262	9

1451	A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality. 2020 , 18, 314-321.e1	3
1450	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. 2020 , 65, 51-64	35
1449	Checkpoint Genes at the Cancer Side of the Immunological Synapse in Bladder Cancer. 2020 , 13, 193-200	8
1448	Prognostic significance of the controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients. 2020 , 38, 76.e11-76.e17	10
1447	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. 2020 , 6, 375-384	110
1446	HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter. 2020 , 18, e443-e449	2
1445	Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. 2020 , 25, 165-174	14
1444	The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. 2020 , 82, 101925	33
1443	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. 2020 , 21, 105-120	35
1442	Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?. 2020 , 15, 35-43	21
1441	Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). 2020 , 20, 8	10
1440	ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. 2020 , 16, 4359-4368	31
1439	Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer. 2020 , 18, e397-e401	3
1438	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. 2020 , 122, 555-563	28
1437	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. 2020 , 126, 1208-1216	37
1436	Studying Rarity in Bladder Cancer. 2020 , 77, 447-448	
1435	Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions. 2020 , 63, 48-63	12
1434	Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer. 2020 , 3, 17-20	7

1433	Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer. 2020 , 100, 104477	6
1432	Erdafitinib for the treatment of metastatic bladder cancer. 2020 , 13, 1-6	33
1431	Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. 2020 , 14, 80-95	6
1430	Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma. 2020 , 80, 1-7	26
1429	Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. 2020 , 39, 2040-2054	48
1428	Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies. 2020 , 27, 108-116	8
1427	Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?. 2020 , 26, 787-792	20
1426	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. 2020 , 25, e398-e404	9
1425	Critical treatment choices for patients with platinum-refractory urothelial carcinoma. 2020 , 21, 11-13	1
1424	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. 2020 , 77, 223-250	60
1423	Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer. 2020 , 47, 35-46	7
1422	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. 2020 , 38, 395-405	216
1421	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. 2020 , 59, 249-256	15
1420	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. 2020 , 26, 1846-1855	35
1419	Reply to F.E. Vera-Badillo et al. 2020 , 38, 651-652	1
1418	Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status: A Systematic Review and Meta-Analysis of Overall Survival Data. 2020 , 43, 193-202	9
1417	The interplay of cell cycle and DNA repair gene alterations in upper tract urothelial carcinoma: predictive and prognostic implications. 2020 , 3, 153-160	0
1416	Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade.. 2020 , 4, 1196-1206	4

1415	Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. 2020 , 12, 1313-1324	3
1414	Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study. 2020 , 31, 1764-1772	7
1413	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. 2020 , 8,	18
1412	Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis. 2020 , 98, 876-883	7
1411	Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder. 2020 , 12,	8
1410	Treatment after progression in the era of immunotherapy. 2020 , 21, e463-e476	50
1409	Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review. 2021 , 19, 208-216.e1	5
1408	[Systemic therapy for metastatic urothelial carcinoma - Current status and what comes after checkpoint inhibitors?]. 2020 , 51, 371-376	1
1407	Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin. 2020 , 12, 8379-8386	5
1406	Immunotherapy in Testicular Germ Cell Tumors. 2020 , 10, 573977	7
1405	Positioning checkpoint blockade in urothelial cancer: PURE-01 and PEANUTS. 2020 , 31, 1601-1602	
1404	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. 2020 , 130, 110621	3
1403	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. 2020 , 23, 101580	10
1402	The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis. 2020 , 99, e22555	2
1401	Bayesian inference using Hamiltonian Monte-Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy. 2020 , 39, 4853-4868	1
1400	The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: A systematic review and meta-analysis. 2020 , 99, e22567	1
1399	Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. 2020 , 21,	17
1398	Immunotherapy in older patients with cancer. 2021 , 44, 260-271	2

1397	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. 2020 , 183, 347-362.e24	128
1396	Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. 2020 , 26, 1839-1844	88
1395	Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study. 2020 , 31, 1755-1763	33
1394	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. 2020 , 26, 1845-1851	72
1393	Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences. 2021 , 7, 1061-1066	0
1392	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. 2020 , 47, 487-510	8
1391	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. 2020 , 34, 312-317	3
1390	Optimizing frontline therapy in advanced urothelial cancer. 2020 , 9, 983-985	1
1389	First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice. 2020 , 9, 986-990	
1388	BORA regulates cell proliferation and migration in bladder cancer. 2020 , 20, 290	0
1387	PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment. 2021 , 39, 4055-4065	3
1386	Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index. 2020 , 105,	11
1385	[Innovations in systemic treatment of urothelial carcinoma]. 2020 , 107, S6-S16	2
1384	Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO. 2020 , 107, eS8-eS15	4
1383	Clinical surveillance in immunotherapy-treated patient. 2020 , 154, 493-495	
1382	CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner. 2020 , 8, 1180-1192	7
1381	Trial watch: IDO inhibitors in cancer therapy. 2020 , 9, 1777625	45
1380	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. 2020 , 5, 109-116	6

1379	Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus. 2020 , 3, 181-183	1
1378	Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. 2020 , 10, 568279	7
1377	Association between tumor mutation burden and immune infiltration in ovarian cancer. 2020 , 89, 107126	9
1376	Optimizing Sequence of PD-L1 Immune-Checkpoint Inhibitors and Radiation Therapy in Bladder Cancer. 2020 , 6, 295-302	2
1375	Review: Brain Metastases in Bladder Cancer. 2020 , 6, 237-248	1
1374	Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice. 2020 , 10, 584834	2
1373	Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma. 2020 , 12, 455-461	3
1372	Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review. 2020 , 21,	6
1371	mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas. 2020 , 8, 1218	2
1370	The human microbiome and genitourinary malignancies. 2020 , 8, 1245	7
1369	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. 2020 , 39, 236	12
1368	Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies. 2020 , 47, 367-379	4
1367	A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. 2020 , 11, 594264	3
1366	Optimal Systemic Treatment of Advanced Bladder Cancer-A Moving Target. 2020 , 12,	
1365	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. 2021 , 7, 1084-1091	0
1364	Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. 2020 , 3, 728-738	27
1363	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. 2020 , 12,	25
1362	Intratumoral Combinatorial Administration of CD1c (BDCA-1) Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. 2020 , 8,	7

1361	Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. 2020 , 10, 570080	2
1360	Bladder Cancer: A Review. 2020 , 324, 1980-1991	195
1359	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). 2020 , 12,	4
1358	lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System. 2020 , 12,	16
1357	Treatment of muscle-invasive and advanced bladder cancer in 2020. 2020 , 70, 404-423	147
1356	A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. 2020 , 126, 4532-4544	2
1355	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. 2020 , 20, 755-763	7
1354	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. 2020 , 12, 1758835920940927	5
1353	Complete remission in a patient with advanced renal pelvis carcinoma with lung metastasis treated with durvalumab immunotherapy: a case report. 2020 , 9, 2408-2413	1
1352	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. 2020 , 114, 102514	14
1351	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. 2020 , 87, 106770	2
1350	Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis. 2020 , 23, 918-927	3
1349	Editorial Comment to Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision. 2020 , 27, 710	
1348	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. 2020 , 8, 672	55
1347	Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report. 2020 , 8, 2050313X20932694	1
1346	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective. 2020 , 11, 1508	30
1345	Inflammatory Manifestations of Systemic Diseases in the Central Nervous System. 2020 , 22, 26	8
1344	Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis. 2020 , 20, 707	11

1343	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. 2020 , 89, 102084	18
1342	Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma. 2020 , 87, 106818	3
1341	The Impact of Histological Variant on Oncological Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. 2020 , 40, 4787-4793	1
1340	Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma. 2020 , 21,	14
1339	A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. 2020 , 126, 4485-4497	12
1338	Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. 2020 , 151, 141-148	24
1337	Sex and Gender Influences on Cancer Immunotherapy Response. 2020 , 8,	22
1336	Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review. 2020 , 6,	7
1335	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. 2020 , 9, 17	13
1334	Immuno-oncology for esophageal cancer. 2020 , 16, 2673-2681	11
1333	Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials. 2020 , 16, e160-e178	2
1332	Long-term trends in sex difference in bladder cancer survival 1975-2009: A population-based study in Osaka, Japan. 2020 , 9, 7330-7340	3
1331	Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. 2020 , 78, 822-830	45
1330	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. 2020 , 10, 1842-1853	61
1329	Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study. 2020 , 10, 568809	1
1328	Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report. 2020 , 10, 564714	4
1327	Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study. 2020 , 38, 851.e11-851.e17	4
1326	Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. 2020 , 9, 1824645	11

1325	Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. 2020 , 12,	1
1324	A "Tail" of Immunotherapy in Metastatic Prostate Cancer. 2020 , 78, 831-833	4
1323	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). 2020 , 13, 143	61
1322	Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy. 2020 , 91, 102116	6
1321	The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. 2020 , 12,	15
1320	Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?. 2020 , 21,	11
1319	Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. 2020 , 10, 15822	5
1318	Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. 2020 , 11, 2023	12
1317	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. 2020 , 43, 291-298	4
1316	Presence of constipation predicts the therapeutic efficacy of pembrolizumab in metastatic urothelial cancer patients. 2020 , 27, 1116-1123	3
1315	Precision oncology in urothelial cancer. 2020 , 5, e000616	0
1314	IL-16 processing in sentinel node regulatory T cells is a factor in bladder cancer immunity. 2020 , 92, e12926	2
1313	Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. 2020 , 11, 1956	45
1312	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. 2020 , 6, 1571-1580	196
1311	Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study. 2020 , 9, 8355-8363	5
1310	Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma. 2020 , 2020, 5848493	1
1309	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020 , 383, 1218-1230	59.2 294
1308	Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. 2020 , 13, 1139-1146	6

1307	Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. 2020 , 38, 489-499.e3	84
1306	Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial. 2020 , 6, 1751-1758	9
1305	Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report. 2020 , 31, 866-871	4
1304	Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. 2021 , 105, 1263-1271	13
1303	Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma. 2020 , 13, 911-922	8
1302	Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer. 2020 , 9, 7729-7741	13
1301	Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. 2020 , 31, 1233-1241	4
1300	Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. 2020 , 11, 1900	2
1299	Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. 2020 , 22, 116	5
1298	Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature. 2020 , 146, 3269-3279	9
1297	Immunotherapy for urothelial carcinoma: Metastatic disease and beyond. 2020 , 16 Suppl 3, 18-23	2
1296	Is There a Role for Immunotherapy in Prostate Cancer?. 2020 , 9,	25
1295	[The use of immune checkpoint inhibitors in routine oncology]. 2020 , 79, 809-817	0
1294	Therapie des metastasierten Urothelkarzinoms. 2020 , 15, 368-376	
1293	Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. 2020 , 50, 1097-1107	5
1292	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. 2020 , 38, 3672-3684	37
1291	A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer. 2020 , 27, e386-e394	3
1290	Multistage Sensitive NanoCRISPR Enable Efficient Intracellular Disruption of Immune Checkpoints for Robust Innate and Adaptive Immune Coactivation. 2020 , 30, 2004940	13

1289	Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration. 2020 , 20, 823	4
1288	Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer. 2020 , 6, 123-129	4
1287	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. 2020 , 3, e2012534	26
1286	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. 2020 , 184, 325-334	9
1285	Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma. 2020 , 111, 3639-3652	5
1284	Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?-Lessons From Value Assessment With ASCO-VF and ESMO-MCBS. 2020 , 11, 574511	0
1283	Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. 2020 , 11, 595655	3
1282	3D Non-Local Neural Network: A Non-Invasive Biomarker for Immunotherapy Treatment Outcome Prediction. Case-Study: Metastatic Urothelial Carcinoma. 2020 , 6,	3
1281	Immunotherapy for advanced or metastatic urothelial carcinoma. 2020 ,	
1280	The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. 2020 , 2020, 6717912	7
1279	PD-1 inhibitors for urothelial cancer: combination or sequential therapy?. 2021 , 396, 1977	0
1278	Enfortumab vedotin - next game-changer in urothelial cancer. 2021 , 21, 801-809	4
1277	Variant histology in bladder cancer: diagnostic and clinical implications.. 2020 , 9, 6565-6575	4
1276	Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions. 2020 , 10, 7102	3
1275	Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. 2020 , 11, 575258	14
1274	Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. 2020 , 12, 5096-5103	
1273	Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer. 2020 ,	1
1272	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. 2020 , 10, 1808-1825	91

1271	Patient-Derived Urothelial Cancer Xenograft Models: A Systematic Review and Future Perspectives. 2020 , 6, 131-141	
1270	Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. 2020 , 11, 587014	17
1269	Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. 2020 , 3, e2017675	8
1268	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. 2020 , 34, 749-762	1
1267	Real-World Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System. 2020 , 4, 918-928	15
1266	Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report. 2020 , 8, 402	4
1265	Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. 2020 , 23, 961-973	13
1264	Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer. 2020 , 30, 428-440	6
1263	Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma. 2020 , 9, 1744897	16
1262	Intervention strategies for microbial therapeutics in cancer immunotherapy. 2020 , 6, 9-17	6
1261	A guide to cancer immunotherapy: from T cell basic science to clinical practice. 2020 , 20, 651-668	746
1260	Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. 2020 , 10,	14
1259	Scientific based combination therapies with immuno-oncology checkpoint inhibitors. 2020 , 86, 1711-1725	4
1258	Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation. 2020 , 14, 2190-2202	7
1257	Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. 2020 , 12,	36
1256	Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma. 2020 , 30, 5392-5403	21
1255	Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. 2020 , 34, 463-476	23
1254	[Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer]. 2020 , 59, 790-796	

1253	Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. 2020 , 30, 547-556	8
1252	Efficacy of immune checkpoint inhibitors and age in cancer patients. 2020 , 12, 587-603	7
1251	Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. 2020 , 6, 43-52	1
1250	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. 2020 , 12,	1
1249	The Changing Landscape of Upper Tract Urothelial Carcinoma Management. 2020 , 145, 316-318	
1248	The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. 2020 , 23, 967-977	6
1247	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. 2020 , 8,	6
1246	Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis. 2020 , 7, 144	6
1245	Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. 2020 , 132, 150-158	14
1244	An evaluation of avelumab for the treatment of genitourinary tumors. 2020 , 20, 971-979	3
1243	[Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments]. 2020 , 59, 810-816	1
1242	Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma. 2020 , 31, 291-300	13
1241	Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. 2020 , 18, 214	15
1240	[Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology]. 2020 , 59, 804-809	1
1239	A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab. 2020 , 131, 104-107	1
1238	Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma. 2020 , 19, 927-934	2
1237	Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer: A Case Report and Literature Review. 2020 , 43, 134-138	2
1236	Immune checkpoint inhibitors in genitourinary malignancies. 2020 , 27, S69-S77	10

1235	Biomarkers of immune checkpoint inhibitor efficacy in cancer. 2020 , 27, S106-S114	13
1234	Histology-agnostic drug development - considering issues beyond the tissue. 2020 , 17, 555-568	25
1233	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. 2020 , 12,	55
1232	Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. 2020 , 18, 235	13
1231	Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis. 2020 , 108, 1274-1288	8
1230	Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision. 2020 , 27, 702-709	18
1229	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. 2020 , 12,	38
1228	Prognostic significance of previous tonsillectomy after radical cystectomy for bladder cancer. 2020 , 54, 297-303	
1227	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. 2020 , 8,	30
1226	Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future. 2020 , 3, 789-801	2
1225	mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. 2020 , 12,	37
1224	Neoadjuvant therapy for muscle-invasive bladder cancer. 2020 , 20, 603-614	4
1223	The emerging role of antibody-drug conjugates in urothelial carcinoma. 2020 , 20, 551-561	9
1222	Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy-Real-World Clinical Impressions and Comparative Review of the Literature. 2020 , 10, 808	4
1221	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. 2020 , 1, 47-68	27
1220	Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis. 2020 , 76, 1345-1354	8
1219	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. 2020 , 22, 70	10
1218	Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. 2020 , 16, 1751-1766	10

1217	The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. 2020 , 10, 261	7
1216	Healthcare and Artificial Intelligence. 2020 ,	2
1215	Regulation of Cancer Immune Checkpoints. 2020 ,	2
1214	Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma. 2020 , 40, 1613-1618	3
1213	Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report. 2020 , 31, 101145	6
1212	'The same old story': thoughts on authorized doses of anticancer drugs. 2020 , 12, 1758835920905412	3
1211	Current Treatment and Outcomes Benchmark for Locally Advanced or Metastatic Urothelial Cancer From a Large UK-Based Single Centre. 2020 , 10, 167	8
1210	Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease. 2020 , 9, 3078-3087	6
1209	Association between myocarditis and other immune-related adverse events secondary to immune checkpoint inhibitor use. 2020 , 147, 1753-1754	8
1208	The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients. 2020 , 38, 602.e1-602.e10	18
1207	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. 2020 , 14, E373-E382	3
1206	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. 2020 , 126, 2597-2606	24
1205	Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer. 2020 , 479, 89-99	21
1204	Mature Versus Registration Studies of Immuno-Oncology Agents: Does Value Improve With Time?. 2020 , 16, e779-e790	1
1203	KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. 2020 , 16, 507-516	25
1202	Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report. 2020 , 13, 43-48	6
1201	Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes. 2020 , 11, 12	44
1200	An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer. 2020 , 21, 863-870	2

1199	Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. 2020 , 395, 1268-1277	133
1198	Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients. 2020 , 20, 175	13
1197	[Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC]. 2020 , 107, S49-S55	0
1196	Limited MOMP, ATM, and their roles in carcinogenesis and cancer treatment. 2020 , 10, 81	4
1195	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. 2020 , 6, 363-392	0
1194	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. 2020 , 9, 1761229	9
1193	Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. 2020 , 4,	1
1192	Role of DNA repair defects in predicting immunotherapy response. 2020 , 8, 23	21
1191	The immunotherapy revolution in genitourinary malignancies. 2020 , 12, 819-831	7
1190	Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study. 2020 , 147, 21-25	6
1189	Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm. 2020 , 17, 707-715	28
1188	Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma. 2020 , 8,	4
1187	Emerging biomarkers in urothelial carcinoma: Challenges and opportunities. 2020 , 25, 100179	3
1186	Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers. 2020 , 11, 1061-1066	4
1185	Antibody-drug conjugates for the treatment of urothelial carcinoma. 2021 , 21, 915-922	1
1184	Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer. 2020 , 10, 10952	3
1183	Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis. 2020 , 2020, 8375348	1
1182	Perioperative systemic chemo-immunotherapy for upper urinary tract urothelial carcinoma. 2020 ,	78

1181	Case of lichen planus pemphigoides after pembrolizumab therapy for advanced urothelial carcinoma. 2020 , 47, e321-e322	5
1180	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. 2020 , 21, 1099-1109	31
1179	Cabozantinib as a choice for platinum-refractory metastatic urothelial cancer. 2020 , 21, 1005-1006	1
1178	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. 2020 ,	39
1177	NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?. 2020 , 17, 491-492	3
1176	Pembrolizumab for the treatment of esophageal cancer. 2020 , 20, 1143-1150	6
1175	Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer. 2020 , 12, 1758835919895753	4
1174	EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. 2020 , 38, 1041-1049	77
1173	Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis. 2019 , 10, 1507	2
1172	Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density. 2020 , 69, 689-702	7
1171	Introducing online multicolumn two-dimensional liquid chromatography screening for facile selection of stationary and mobile phase conditions in both dimensions. 2020 , 1622, 460895	13
1170	Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. 2020 , 10, 2083	60
1169	PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. 2020 , 477, 269-277	7
1168	Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans. 2019 , 9, 1493	21
1167	Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway. 2020 , 111, 1165-1179	28
1166	Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature. 2020 , 25, 369-374	7
1165	Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. 2020 , 50, 800-809	6
1164	Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwan-Japan UTUC Collaboration Cohort. 2020 , 27, 327-332	6

1163	High-dose vitamin C enhances cancer immunotherapy. 2020 , 12,	65
1162	Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors. 2020 , 3, 25-27	6
1161	Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics. 2020 , 10, 3565	17
1160	Assessing Treatment Benefit in Immuno-oncology. 2020 , 12, 83-103	4
1159	Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. 2020 , 17, 100536	6
1158	Combination therapy with oncolytic viruses and immune checkpoint inhibitors. 2020 , 20, 635-652	17
1157	Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer. 2020 , 77, 346-351	16
1156	A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model. 2020 , 148, 102896	6
1155	Methods to assess anticancer immune responses in orthotopic bladder carcinomas. 2020 , 635, 127-137	1
1154	The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials. 2020 , 22, 1750-1761	1
1153	MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. 2020 , 38, 488-495	8
1152	Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist. 2020 , 63, 35-49	1
1151	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. 2020 , 143, 1-11	14
1150	Management of bladder cancer in older patients: Position paper of a SIOG Task Force. 2020 , 11, 1043-1053	22
1149	The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. 2020 , 11, 369-379	12
1148	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. 2020 , 25, 290-300	28
1147	Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma. 2020 , 98, 237-242	12
1146	The importance of exosomal PDL1 in tumour immune evasion. 2020 , 20, 209-215	165

1145	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials. 2020 , 15, e0227344	13
1144	Emerging intravesical therapies for the management of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward. 2020 , 14, 204-213	6
1143	Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases. 2020 , 126, 91-92	0
1142	TCR Repertoire Diversity of Peripheral PD-1CD8 T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. 2020 , 8, 146-154	72
1141	Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review. 2020 , 12,	17
1140	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. 2020 , 21,	11
1139	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. 2020 , 77, 548-556	19
1138	Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. 2020 , 17, 77-106	45
1137	PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. 2020 , 477, 83-91	23
1136	Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis. 2020 , 38, 130-138	7
1135	Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer. 2020 , 9, 2190-2200	15
1134	Codelivery of Anti-PD-1 Antibody and Paclitaxel with Matrix Metalloproteinase and pH Dual-Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy. 2020 , 16, e1906832	43
1133	Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. 2020 , 125, 739-746	7
1132	Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer. 2020 , 9,	8
1131	The top 100 most cited manuscripts in bladder cancer: A bibliometric analysis (review article). 2020 , 75, 130-138	13
1130	Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. 2020 , 18, 15	37
1129	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. 2020 , 38, 1154-1163	130
1128	Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice. 2020 , 25, 899-905	21

1127	Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. 2020 , 18, 351-360.e3	6
1126	Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature. 2020 , 8, 24-32	5
1125	Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. 2020 , 122, 771-777	21
1124	Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. 2020 , 15, e0231936	11
1123	Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers. 2020 , 154, 102891	1
1122	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. 2020 , 26, 61-70	14
1121	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. 2020 , 12,	397
1120	Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression. 2020 , 83, 106478	21
1119	Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer. 2020 , 25, 680-688	6
1118	Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. 2020 , 22, 2130-2135	15
1117	Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. 2020 , 131, 40-50	62
1116	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. 2020 , 39, 4077-4091	8
1115	Learning from clinical trials of neoadjuvant checkpoint blockade. 2020 , 26, 475-484	46
1114	Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. 2020 , 30, 1458-1469	12
1113	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis. 2020 , 43, 95-103	3
1112	Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability. 2020 , 8,	3
1111	Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction. 2020 , 10, 699	14
1110	Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype. 2020 , 12,	7

1109	Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. 2020 , 40, 1-11	18
1108	Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. 2020 , 21,	6
1107	The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis. 2020 , 126, 26-54	2
1106	A randomised Phase II trial of carboplatin and gemcitabine + vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. 2020 , 126, 292-299	1
1105	Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters. 2020 , 9, 19	2
1104	Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. 2020 , 126, 3021-3030	52
1103	Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?. 2020 , 12, 351-354	34
1102	Immunotherapy. 2020 ,	1
1101	[Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma]. 2020 , 59, 533-543	1
1100	Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials. 2020 , 9, 1746113	8
1099	Emerging treatments in advanced urothelial cancer. 2020 , 32, 232-239	1
1098	Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. 2020 , 30, 457-466	1
1097	Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis. 2020 , 19, 802-811	8
1096	ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. 2020 , 21, 344	1
1095	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. 2020 , 26, 2087-2095	17
1094	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. 2020 , 38, 1797-1806	56
1093	Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients. 2020 , 27, 4035-4043	5
1092	Role and efficacy of current biomarkers in bladder cancer. 2020 , 5, 6-6	5

1091	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. 2020 , 12,	18
1090	Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis. 2021 , 110, 50-60	6
1089	Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma. 2021 , 105, 48-56	2
1088	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. 2021 , 79, 82-104	356
1087	Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study. 2021 , 107, 32-38	2
1086	VEGF inhibition in urothelial cancer: the past, present and future. 2021 , 39, 741-749	4
1085	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. 2021 , 80, 36-48	61
1084	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. 2021 , 79, 62-79	176
1083	Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study. 2021 , 74, 53-57	4
1082	The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma. 2021 , 10, 30	
1081	Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. 2021 , 4, 297-300	4
1080	PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. 2021 , 39, 1345-1355	5
1079	Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gñez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic	
1078	Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers. 2021 , 147, 119-126	7
1077	Recent advances in nanoscale materials for antibody-based cancer theranostics. 2020 , 173, 112787	6
1076	Updates in the management and future landscape of urothelial carcinoma. 2021 , 27, 435-444	0
1075	Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies. 2021 , 13, 95-101	1
1074	PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?. 2021 , 23, e3294	6

1073	Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer. 2021 , 17, e125-e131	0
1072	Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. 2021 , 24, 140-149	5
1071	Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma. 2021 , 39, 75.e1-75.e8	2
1070	Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2021 , 127, 90-95	2
1069	Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. 2021 , 26, 169-177	15
1068	Chemotherapy and Immunotherapy in Urologic Oncology. 2021 ,	
1067	Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. 2021 , 26, 49-55	9
1066	An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma. 2021 , 27, 330-341	38
1065	From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer. 2021 , 13, 67-77	1
1064	Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions. 2021 , 39, 1319-1329	10
1063	Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center. 2020 , 148, 2502	1
1062	TOX-expressing terminally exhausted tumor-infiltrating CD8 T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. 2021 , 499, 137-147	13
1061	Advances in bladder cancer biology and therapy. 2021 , 21, 104-121	80
1060	Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. 2020 , 22, 7	3
1059	A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma. 2021 , 157, 103173	2
1058	Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker. 2020 , 23, 5	11
1057	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. 2021 , 127, 840-849	14
1056	Pasotuxizumab, a BiTE immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. 2021 , 13, 125-141	29

1055	Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. 2021 , 149, 277-286	2
1054	Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need. 2021 , 21, 299-313	2
1053	Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?. 2021 , 13, 91-93	0
1052	Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. 2021 , 12, 1133-1143	4
1051	Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients. 2021 , 35, 61-73	
1050	Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience. 2021 , 19, 176-181	1
1049	Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review. 2021 , 91, 107281	12
1048	Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study. 2021 , 41, 37-50	9
1047	Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review. 2021 , 61, 282-297	1
1046	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. 2021 , 39, 154-173	92
1045	Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes. 2021 , 53, 56-66	5
1044	Sonodynamic therapy-derived multimodal synergistic cancer therapy. 2021 , 497, 229-242	33
1043	PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy. 2021 , 39, 195.e15-195.e23	0
1042	Immune checkpoint inhibition in upper tract urothelial carcinoma. 2021 , 39, 1357-1367	14
1041	Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. 2021 , 55, 772-782	6
1040	Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. 2021 , 70, 657-665	7
1039	Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. 2021 , 39, 1331-1343	13
1038	Current status and future perspectives of immunotherapy in bladder cancer treatment. 2021 , 64, 512-533	5

1037	Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. 2021 , 23, 882-891	1
1036	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. 2021 , 78, 867-887	5
1035	Novel Adjuvant Therapies for Upper Tract Urothelial Carcinoma After Endoscopic Management. 2021 , 429-438	
1034	The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death. 2021 , 28, 800-813	1
1033	Safety and efficacy analysis of pembrolizumab dosing patterns in patients with advanced melanoma and non-small cell lung cancer. 2022 , 28, 87-95	1
1032	Evolving Therapies for Urothelial Carcinoma: Novel Paradigms and Future Directions. 2021 , 16, 82	0
1031	Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma. 2021 , 10, 1887-551	0
1030	Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program. 2021 , 13, 17588359211015499	0
1029	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). 2021 , 15, 11795549211021667	1
1028	Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis. 2021 ,	12
1027	Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy. 2021 , 35, 2869-2874	0
1026	Radioimmunotherapy: future prospects from the perspective of brachytherapy. 2021 , 13, 458-467	1
1025	Modification of Platinum-based Systemic Chemotherapy for Advanced Urothelial Carcinoma in Patients With Suboptimal Renal Function. 2021 , 35, 2821-2829	0
1024	ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition.	1
1023	Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy. 2020 , 11, 563258	3
1022	Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study. 2021 , 25, 479-487	6
1021	Clinical Trials in Localized Muscle-Invasive Bladder Cancer. 2021 , 355-363	
1020	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. 2021 , 13,	51

1019	The Impact of Priming Effect of Immune Checkpoint Inhibitor Therapy for Advanced Stage Non-Small Cell Lung Cancer: A Meta-Epidemiological Study.	
1018	The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack. 2021 , 13,	8
1017	Behandlungsoptionen medikamentöser Therapie des Harnblasenkarzinoms. 2021 , 1-3	
1016	Regulation of PD-L1 expression in the tumor microenvironment. 2021 , 14, 10	65
1015	Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. 2021 , 9,	27
1014	Immunotherapy for Metastatic Urothelial Carcinoma. 2021 , 305-313	
1013	Perioperative therapy in muscle invasive bladder cancer. 2021 , 37, 226-233	0
1012	Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma. 2021 , 13, 17588359211039052	2
1011	Immunotherapy in Immunosuppressed Patients. 2021 , 429-440	
1010	Bladder Cancer. 2021 ,	0
1009	Bladder Cancer Tissue-Based Biomarkers. 2021 , 2, 53-71	
1008	Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multi-peptide vaccinations: a case report. 2021 , 9,	1
1007	Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti-PD-1 Treatment Efficacy in Urothelial Carcinoma. 2021 , 22,	4
1006	Pembrolizumab Combined Chemotherapy With Gemcitabine and Paclitaxel: A Comparative Assessment of Clinical Outcomes in Patients With Platinum-refractory Advanced Urothelial Cancer. 2021 , 35, 1889-1894	0
1005	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. 2021 , 83-99	
1004	Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. 2021 , 39, 860-870	4
1003	Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. 2021 , 39, 812-820	4
1002	Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis. 2021 , 10, 1878599	4

1001	Medical Treatment with Targeted Therapy for Metastatic Urothelial Bladder Carcinoma. 2021 , 199-209	
1000	Severe colitis induced by pembrolizumab in a patient with advanced hypopharyngeal squamous cell carcinoma: A case report of an immune-related adverse event. 2021 , 8, 113	0
999	[Systemic treatment of bladder cancer]. 2021 , 60, 247-258	0
998	Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma. 2021 , 16, 189-196	1
997	Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder. 2021 , 23, 24	0
996	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment. 2021 , 19, 30-39	
995	External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy. 2021 , 26, 100344	0
994	Are radiologists ready to evaluate true response to immunotherapy?. 2021 , 12, 29	2
993	Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. 2021 , 13,	3
992	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. 2021 , 47, S33-S44	0
991	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. 2021 , 205, 414-419	1
990	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. 2021 , 128, 196-205	3
989	B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors. 2021 , 28, 135-149	3
988	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. 2021 , 53, 141-156	25
987	Status of Metastatic Bladder Cancer Treatment Illustrated by a Case. 2021 , 37, 151113	0
986	PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. 2021 , 22, 162-170	5
985	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. 2021 ,	5
984	FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review. 2021 , 27, 3522-3527	6

983	Wnt/ β -Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma. 2021 , 13,	6
982	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. 2021 , 18, 345-362	148
981	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. 2021 , 27, 2424-2429	12
980	Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma. 2021 , 12,	1
979	Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. 2021 , 70, 2559-2576	9
978	Extrapolating Parametric Survival Models in Health Technology Assessment Using Model Averaging: A Simulation Study. 2021 , 41, 476-484	3
977	Cáncer de vejiga. 2021 , 13, 1441-1453	
976	Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis. 2021 , 27, 240-255	2
975	Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future. 2021 , 93, 102142	8
974	The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors. 2021 , 6, 100008	3
973	Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer. 2021 , 41,	7
972	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. 2021 , 6, 72	50
971	Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. 2021 , 26, 397-405	4
970	Cell Therapies in Bladder Cancer Management. 2021 , 22,	2
969	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 1125-1135	59.2 110
968	Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development. 2021 , 11, 2957-2972	7
967	Successful pembrolizumab treatment of microsatellite instability-high intrahepatic cholangiocarcinoma: A case report. 2021 , 9, 2259-2263	0
966	The evolving treatment landscape of advanced urothelial carcinoma. 2021 , 33, 221-230	2

965	Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer. 2021 , 4, 943-943	4
964	Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. 2021 , 13,	7
963	Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer. 2021 , 9, 646982	3
962	Therapeutic Applications of Monoclonal Antibodies in Urologic-Oncology Management - An Update.	
961	NFB-Activated COX2/PGE/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues. 2021 , 13,	4
960	Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy. 2021 , 14, 1981-1988	3
959	Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials. 2021 , 13,	3
958	Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma. 2021 , 70, 2981-2990	2
957	Stereotactic Body Radiotherapy for Palliation of Hematuria Arising From Urothelial Carcinoma of the Kidney in Unfavorable Surgical Candidates. 2021 , 44, 175-180	0
956	Predictive biomarkers in bladder cancer. 2021 , 15, 241-246	0
955	The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: Primer. 2021 , 3, 35-47	25
954	Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. 2021 , 159, 103241	5
953	Biomarker-Oriented Therapy in Bladder and Renal Cancer. 2021 , 22,	6
952	Population-based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non-metastatic muscle-invasive bladder cancer. 2021 , 10, 2636-2644	1
951	Coming of Age of Immunotherapy of Urothelial Cancer. 2021 , 16, 283-294	1
950	The Controlling Nutritional Status (CONUT) Score is a Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with First-Line Platinum-Based Chemotherapy. 2021 , 7, 13-21	0
949	Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5. 2021 , 53, 1166-1173	1
948	Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. 2021 , 22,	6

947	Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review. 2021 , 39, 161-170	8
946	Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting. 2021 , 26, 1057-1064	1
945	Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. 2021 , 11, 621591	14
944	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. 2021 , 13,	2
943	The Diagnosis and Treatment of Patients With Bladder Carcinoma. 2020 , 118,	3
942	Paradigms on Immunotherapy Combinations with Chemotherapy. 2021 , 11, 1353-1367	43
941	[Avelumab after platinum-based chemotherapy]. 2021 , 60, 640-641	
940	Narrative review: update on immunotherapy and pathological features in patients with bladder cancer. 2021 , 10, 1521-1529	5
939	DNA methylation as predictive marker of response to immunotherapy?. 2021 , 14, 150-153	0
938	Profound and durable responses with PD-1 immune checkpoint inhibitors in patients with metastatic penile squamous cell carcinoma. 2021 , 3, 100045	1
937	Therapeutic applications of the cancer immunoediting hypothesis. 2021 ,	5
936	Current Immunotherapies for Glioblastoma Multiforme. 2020 , 11, 603911	15
935	Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma. 2021 , 14, 91	1
934	Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, what's new?. 2021 , 13, 459-463	2
933	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. 2021 , 299, 109-119	14
932	Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma. 2021 , 21, 60	4
931	Rectal metastasis from bladder urothelial carcinoma: a case report. 2021 , 7, 100	0
930	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. 2021 , 11, 562315	3

929	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. 2021 , 13, 419-432	3
928	Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma. 2021 , 25, E1-E9	3
927	PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy. 2021 , 11,	0
926	Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study. 2021 , 13,	1
925	Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine. 2021 , 8, 2100166	2
924	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. 2021 , 4, 170-179	7
923	Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms?. 2021 , 13,	6
922	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. 2021 , 20, 685-694	5
921	Routine Molecular Pathology Diagnostics in Precision Oncology. 2021 , 118,	
920	Systemic therapy and COVID19: Immunotherapy and chemotherapy. 2021 , 39, 213-220	2
919	Complete metabolic response with [F]fluorodeoxyglucose-positron emission tomography/computed tomography predicts survival following induction chemotherapy and radical cystectomy in clinically lymph node positive bladder cancer. 2021 ,	3
918	Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. 2021 ,	2
917	Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy. 2021 , 12, 642800	9
916	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. 2021 , 22, 525-537	73
915	Therapeutic potential of interleukin-15 in cancer (Review). 2021 , 22, 675	7
914	Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study. 2021 , 3008916211004733	1
913	PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays. 2021 , 479, 705-713	
912	Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. 2021 , 332, 109-126	12

911	Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer. 2021 , 7, 633-634	
910	Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study. 2021 , 6, 100090	6
909	Panels and models for accurate prediction of tumor mutation burden in tumor samples. 2021 , 5, 31	1
908	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. 2021 , 27, 4287-4300	9
907	The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma. 2021 , 39, 832.e17-832.e23	2
906	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. 2021 , 11, 650292	3
905	p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma. 2021 , 11, 651754	
904	Development of a bispecific immune engager using a recombinant malaria protein. 2021 , 12, 353	1
903	Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer-Reply. 2021 , 7, 634-635	
902	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. 2021 , 19, 125-134	1
901	Sequential therapies for advanced urothelial cancer: Hope meets new challenges. 2021 , 160, 103248	2
900	Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy. 2021 , 11, 646883	2
899	Checkpoint inhibition in combination with an immunoblast of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. 2021 , 21, 514	1
898	Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort. 2021 , 10, 3188-3196	4
897	Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes. 2021 , 13,	2
896	Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. 2021 , 9,	7
895	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. 2021 , 27, 793-801	18
894	Targeting the VEGF Pathway in Osteosarcoma. 2021 , 10,	3

893	Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody. 2021 , 11, 10264	
892	Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer. 2021 , 5, 722-724	0
891	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. 2021 , 11, 621639	8
890	promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. 2021 , 9,	8
889	Cancer Therapeutics-related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation. 2021 , 44, 179-184	1
888	Effectiveness and safety of combined therapy versus monotherapy based on immune checkpoint inhibitors and/or targeted drugs as salvage treatment for advanced urothelial carcinoma: a systematic review and meta-analysis.. 2021 , 10, 2091-2107	
887	Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer. 2021 , 21, 646	
886	The Landscape of Antibody-drug Conjugates in Urothelial Cancer. 2021 , 1, 273-282	
885	Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials. 2021 , 4, e218175	1
884	Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. 2021 , 13,	1
883	Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. 2021 , 19, 191-207	0
882	High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy. 2021 , 13,	5
881	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. 2021 , 14, 101056	5
880	Efficacy and safety of adjuvant therapy with nivolumab or placebo in high-risk patients with muscle-invasive urothelial carcinoma after radical surgery: review of the first results of the randomized phase III trial CheckMate 274. 2021 , 17, 108-119	
879	Atlantis exploration: predictive biomarkers to immunotherapy response. 2021 , 17, 167-177	0
878	A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma. 2021 , 14, 29	4
877	Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model. 2021 , 205, 1336-1343	5
876	Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). 2021 , 21, 593	7

875	Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. 2021 , 21, 863-873	1
874	Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis. 2021 , 11, 696716	2
873	The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors. 2021 , 26, e1205-e1215	2
872	Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. 2021 , 13,	1
871	Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. 2021 , 11, 662392	1
870	Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study. 2021 , 28, 899-905	2
869	[Systemic treatment of bladder cancer]. 2021 , 60, 1167-1174	1
868	Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan. 2021 , e1398	6
867	Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. 2021 , 1-11	0
866	Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study. 2021 , 11, 671969	1
865	Treatment of advanced urogenital cancers with immune checkpoint inhibitors. 2021 , 64, 349-357	
864	Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation. 2021 , 11, 643413	1
863	Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report. 2021 , 11, 646322	0
862	Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis. 2021 , 11, 645245	2
861	Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. 2021 , 149, 49-60	
860	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. 2021 ,	2
859	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. 2021 , 22,	16
858	Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma. 2021 , 1	1

857	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. 2021 , 97, 102187	9
856	Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. 2021 , 6, 100118	8
855	A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report. 2021 , 11, 671416	4
854	Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. 2021 , 13,	3
853	Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin. 2021 , 13,	1
852	CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway. 2021 , 507, 70-79	1
851	Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors. 2021 , 14, 100	5
850	The dark side of immunotherapy. 2021 , 9, 1041	2
849	mRNA translation is a therapeutic vulnerability necessary for bladder epithelial transformation. 2021 , 6,	2
848	High T-cell infiltration in tumor tissue and younger age predict the response to pembrolizumab in recurrent urothelial cancer. 2021 , 54, 316-323	0
847	An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. 2021 , 12, 707930	1
846	Current Therapy for Metastatic Urothelial Carcinoma. 2021 , 35, 469-493	0
845	Preclinical Models for Bladder Cancer Research. 2021 , 35, 613-632	1
844	Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer. 2021 , 10, 5375-5391	2
843	Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. 2021 , 9,	2
842	Characterizing the molecular and immune landscape of canine bladder cancer. 2021 ,	1
841	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. 2021 , 4, 464-472	9
840	Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. 2021 , 13, 15413-15432	1

839	Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors: A Population-based Study Using SEER-Medicare Data. 2021 , 44, 413-418	2
838	Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis. 2021 ,	1
837	SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy. 2021 , 6, 100152	1
836	Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. 2021 ,	0
835	Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma. 2021 , 4, 310-313	0
834	Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets.. 2021 , 28, 100279	
833	Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies. 2021 , 21, 205	5
832	Immunotherapy in breast cancer: A clinician's perspective. 2021 , 1, 47-57	4
831	Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. 2021 , 9,	8
830	Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples. 2021 , 12, 599207	5
829	Advancing to the era of cancer immunotherapy. 2021 , 41, 803-829	27
828	Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma. 2021 , 3, 115-136	2
827	Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management. 2021 , 41, e182-e189	1
826	Immunotherapy in the treatment of lymphoma. 2021 , 13, 503-520	2
825	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. 2021 , 126, 630-638	6
824	New Kids on the Block – The Game Changers. The Role of Immune Check Point Blockade in Personalised Treatment of Prostate, Urinary Bladder and Kidney Cancer. 2021 , 75, 149-157	1
823	The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review. 2021 , 26, e1381-e1394	0
822	Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. 2021 , 44, 248-253	2

821	Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer Models. 2021 , 9, 690358	2
820	Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model. 2021 , 26,	2
819	Immunotherapy in endometrial cancer: rationale, practice and perspectives. 2021 , 9, 49	6
818	The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics. 2021 , 19, 1778-1791	2
817	A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics. 2021 , 23, 2415-2430	6
816	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. 2021 , 53, 961-978	2
815	Is There a Benefit of Combining Immunotherapy and Radiotherapy in Bladder Cancer?. 2021 , 33, 407-414	1
814	Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge. 2021 , 2021, 9087529	
813	Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era. 2021 , 73, 292-298	2
812	Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor. 2021 ,	1
811	Cutaneous metastasis emerging during chemotherapy and progressing during immunotherapy for urothelial carcinoma. 2021 , 4, 363-366	
810	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. 2021 , 9,	2
809	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. 2021 , 22, 931-945	63
808	CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. 2021 , 9,	5
807	Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. 2021 , 80, 113	
806	Successful treatment of metastatic bladder cancer by gemcitabine-cisplatin re-challenge after pembrolizumab. 2021 , 4, 360-362	
805	Approaches to Non-Muscle-Invasive Bladder Cancer. 2021 , 23, 105	3
804	Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma. 2021 , 39, 834.e21-834.e28	0

803	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. 2021 , 163, 103376	3
802	Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. 2021 , 16, e0241766	2
801	LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. 2021 , 11,	1
800	Immunotherapy in Older Adults With Cancer. 2021 , 39, 2115-2127	10
799	Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. 2021 , 12, 640099	0
798	Comparative pharmacoeconomic analysis of biologicals used for metastatic urothelial carcinoma. 2021 , 17, 112-127	
797	Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives. 2021 , 22,	2
796	Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data. 2021 ,	1
795	The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. 2021 , 12, 670391	8
794	Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. 2021 , 80, 7-11	12
793	TMB or not TMB as a biomarker: That is the question. 2021 , 163, 103374	19
792	Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. 2021 , 22, 919-930	53
791	Pembrolizumab use in bladder cancer: a tale of two trials. 2021 , 18, 577-578	2
790	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. 2021 , 151, 35-48	7
789	Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer. 2021 , 28, 970-974	3
788	Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR. 2021 , 1	3
787	Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma. 2021 , 1	2
786	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. 2021 , 12, 714483	3

785	Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. 2021 , 39, 788.e15-788.e21	0
784	Postoperative and Survival Outcomes After Cytoreductive Surgery in the Treatment of Metastatic Upper Tract Urothelial Carcinoma. 2021 , 153, 244-249	
783	Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy. 2021 ,	0
782	Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer. 2021 , 57,	5
781	The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. 2021 , 11, 667650	2
780	Editorial Comment to Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer. 2021 , 28, 975	
779	Molecular pathology of urothelial carcinoma. 2021 , 113, 67-83	4
778	Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. 2021 , 125, 1251-1260	9
777	Real-World Study of Treatment with Pembrolizumab Among Patients with Advanced Urothelial Tract Cancer in Denmark. 2021 , 1-13	1
776	Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching. 2021 ,	0
775	Pan-Cancer Prognostic Role and Targeting Potential of the Estrogen-Progesterone Axis. 2021 , 11, 636365	1
774	Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan. 2021 , 13,	1
773	Liver Inflammation and Hepatobiliary Cancers. 2021 , 7, 606-623	10
772	Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. 2021 , e1739	6
771	Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. 2021 , 110, 738-741	10
770	Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. 2021 , 40, 949-982	17
769	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. 2021 , 26, e1786-e1799	11
768	Palliative care physicians' recognition of patients after immune checkpoint inhibitors and immune-related adverse events. 2022 , 30, 775-784	

767	Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer. 2021 , 30, 34-36	1
766	Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies. 2021 , 10,	2
765	Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. 2021 , 26, 1017-1025	1
764	Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. 2021 , 26, 1026-1034	1
763	Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug. 2021 , 135, 543-555	2
762	High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma. 2021 , 17, 2893-2905	0
761	Autophagy controls programmed death-ligand 1 expression on cancer cells (Review). 2021 , 15, 84	3
760	Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma. 2021 , 12, 723066	
759	Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions. 2021 , 13,	4
758	CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma. 2021 , 132, 202-209	4
757	Urothelial carcinoma in the era of immune checkpoint inhibitors. 2021 , 13, 953-964	1
756	Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. 2021 , 131,	7
755	Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. 2021 ,	1
754	Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. 2021 , 4, e2122998	2
753	Metavariabes Resuming Host Immune Features and Nodal Involvement Are Associated with Oncological Outcomes in Oral Cavity Squamous Cell Carcinoma. 2021 , 10,	1
752	Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy. 2021 , 40, 63.e19-63.e19	0
751	Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. 2021 , 7, 1536-1543	5
750	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. 2021 , 17, 3137-3150	8

749	Predictive Value of the // Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy. 2021 , 12, 643282	4
748	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. 2021 , 39, 2474-2485	57
747	Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study. 2021 , 11, 15623	1
746	Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. 2021 , 39, 2443-2451	27
745	Roles of CCL2-CCR2 Axis in the Tumor Microenvironment. 2021 , 22,	7
744	Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. 2021 , 13, 917-929	0
743	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. 2021 , 13,	8
742	Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder. 2021 , 40, 107.e11-107.e11	
741	The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials. 2021 , 13, 20468-20480	0
740	Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma. 2021 ,	0
739	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 385, 683-694	59.2 73
738	Prognostic Role of Programmed Death Ligand-1 on Tumor-Infiltrating Immune Cells in "High-Risk" Patients Following Radical Cystectomy: A Retrospective Cohort Study. 2021 , 11, 706503	0
737	Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review. 2021 , 11, 705294	2
736	Current status and future perspectives of immunotherapy against urothelial and kidney cancer. 2021 , 51, 1481-1492	2
735	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. 2021 , 23, 319-326	1
734	Do the benefits of being a smoker hint at the existence of PD-1/PD-L1 sensitizers for patients on single-agent immunotherapy?. 2021 , 9,	2
733	Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab. 2021 , 28, 1261-1267	3
732	A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab. 2021 , 57,	

731	Re: Thomas Powles, Tibor CsEzi, Mustafa EgfoU, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press.	
730	https://doi.org/10.1016/S1470-2045(21)00152-2 : The Conflict of Adding Immunotherapy to Chemotherapy in Metastatic Urothelial Carcinoma: A Matter of the Right Timing?. 2021 , 4, 854 Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling. 2021 , 13,	5
729	The effect of patient sex on the efficacy and safety of anticancer immunotherapy. 2021 , 20, 1535-1544	1
728	Recent Advances in the Management of Patients with Non-Muscle-Invasive Bladder Cancer Using a Multidisciplinary Approach: Practical Recommendations from the Spanish Oncology Genitourinary (SOGUG) Working Group. 2021 , 13,	1
727	From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1-Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?. 2021 , 11,	0
726	Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. 2021 , 13,	4
725	Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib. 2021 , 9, 730240	0
724	Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy. 2020 , 20, 517-524	5
723	Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. 2020 , 35, 834-853	8
722	Bladder Cancer Academy 2018 Selected Summaries. 2018 , 20, 31-37	3
721	Pathophysiology of diabetes: An overview. 2020 , 10, 174-188	17
720	Low doses in immunotherapy: Are they effective?. 2019 , 2, 54	4
719	Cancer Immunotherapy: An Impossible Dream for the Common Man?. 2020 , 41, 312-316	1
718	New therapies in nonmuscle invasive bladder cancer treatment. 2018 , 34, 11-19	23
717	Should We Design Clinical Trials Differently in the Era of Cancer Immunotherapy?. 2019 , 2, 36-39	2
716	Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy. 2019 , 8, 65-68	3
715	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. 2020 , 20, e8	9
714	Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report. 2018 , 50, 1458-1461	7

713	Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. 2020 , 52, 594-603	30
712	[PREDICTIVE AND PROGNOSTIC SIGNIFICANCE OF PRE-TREATMENT LYMPHOCYTE COUNT IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA TREATED WITH PLATINUM-BASED FIRST-LINE CHEMOTHERAPY]. 2019 , 110, 160-167	1
711	Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. 2019 , 17, 750-757	52
710	Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time. 2020 , 18, 278-285	5
709	Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling. 2020 , 8, e10414	5
708	Harnessing the Immunomodulatory Effects of Radiation in Urinary Bladder Cancer. 2019 , 11, e4108	4
707	Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab. 2021 , 35, 3563-3568	0
706	Adjuvant Therapy Options for Urological Neoplasms. 2021 , 214-222	
705	Digital pathology and artificial intelligence in translational medicine and clinical practice. 2021 ,	19
704	Pan-cancer analysis of the prognostic and immunological role of PSMB8. 2021 , 11, 20492	4
703	Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab. 2021 , 1	1
702	Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma. 2021 , 4, 1178	0
701	Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?. 2021 , 13,	4
700	Temozolomide abrogates the aggressiveness of urothelial carcinoma cells by enhancing senescence and depleting the side population. 2021 , 22, 845	
699	Persistent deficiencies in the measurement and reporting of tobacco use in contemporary genitourinary oncology clinical trials. 2021 , 78, 102022	
698	FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab. 2021 , 11, 21199	1
697	Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. 2022 , 34, 95-106	1
696	The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab. 2021 , 13, 8049-8056	1

- 695 Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8 T cells. **2021**, 1
- 694 The emerging treatment landscape of advanced urothelial carcinoma. **2021**, 15, 247-252 0
- 693 An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment. **2021**, 13, 1
- 692 The Role of Kinase Inhibitors in Cancer Therapies.
- 691 Emerging biomarkers in metastatic urothelial carcinoma: tumour mutational burden, PD-L1 expression and APOBEC polypeptide-like signature in a patient with complete response to anti-programmed cell death protein-1 inhibitor. **2021**, 15, 1306
- 690 Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. **2021**, 0
- 689 Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis. **2021**, 1 0
- 688 Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. **2021**, 158, 47-62 7
- 687 Efficacy of Different Second-line Therapy Regimens in Metastatic Urothelial Carcinoma. **2017**, 10, 52-58
- 686 Immunotherapy in urothelial cancer: recent data and perspectives. **2018**, 13, 16-24 2
- 685 Bladder Cancer in Older Adults. **2018**, 1-18
- 684 Neue Arzneimittel 2017. **2018**, 53-148
- 683 Immune Checkpoint Inhibition. **2018**, 315-353
- 682 The Role of Medical Oncologist. **2018**, 119-122
- 681 Harnblasenkarzinom. **2018**, 243-282
- 680 Novel Options in Metastatic and Non-surgically Curable Bladder Cancer. **2018**, 14, 87
- 679 Immunotherapy and New Combinations in Muscle-Invasive Bladder Cancer. **2018**, 91-98
- 678 Enjeux et difficult s de la gestion des m dicaments on eux non int gr s dans la liste en sus pour un h pital traitant des cancers. **2018**, 202, 1003-1012

- 677 33rd Annual Congress of the European Association of Urology in 2018: Review of oncological topics. **2018**, 14, 177-182 0
- 676 REVIEW OF THE ONCOLOGICAL UROLOGY PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2018 ANNUAL MEETING. **2018**, 14, 143-148 0
- 675 BLADDER CANCER: MEDICAL TREATMENT STRATEGIES. **2018**, 14, 85-91 1
- 674 Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study. **2019**, 14, 31-36
- 673 Immune Checkpoint Inhibitors and Novel Agents in the Treatment of Metastatic Urothelial Cancer Current Status and Future Perspectives. **2019**, 15, 68
- 672 Landmark Trials in Selected Genitourinary Malignancies. **2019**, 75-121
- 671 The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape.. **2019**, 8, S130-S132
- 670 Precision oncology: myth or reality?. **2019**, 5-14
- 669 Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab. **2019**, 11, e4862 2
- 668 Immunotherapy in the treatment of urological malignancies. **2019**, 20, 112-115
- 667 Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progression.
- 666 Antibody Targeting of B7-H4 Enhances the Immune Response in Urothelial Carcinoma.
- 665 The Systematic Review of the Efficacy and Safety of Immune Checkpoint Inhibitor in Urological Cancers. **2019**, 17, 75-80
- 664 The importance of not only living longer but also better in the setting of advanced urothelial cancer. **2019**, 7, S187
- 663 Genitourinary Tumors. **2020**, 133-147
- 662 Real World Outcomes of Check Point Inhibitors Immunotherapy in Renal and Urothelial Cancers in a Tertiary Care Cancer Center in India. 4, 63-66
- 661 Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study. **2019**, 51, 1269-1274 1
- 660 Bladder Cancer in Older Adults. **2020**, 671-688

- 659 ATLANTIS: An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in patients with metastatic urothelial cancer.
- 658 Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma. **2020**, 19, 2943-2949 2
- 657 Improving Outcomes for Patients With Advanced Urothelial Carcinoma. **2020**, 11, 285-289
- 656 Latest progress in molecular biology and treatment in genitourinary tumours. **2020**, 22, 2175-2195 1
- 655 Treating Elderly Patients With Muscle-Invasive Bladder Cancer. **2020**, 18, 783-790 3
- 654 Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin. **2020**, 11, 412-417
- 653 Clinical surveillance in immunotherapy-treated patient. **2020**, 154, 493-495
- 652 DERN CONTROL POINT INHIBITORS AND THEIR POSSIBILITIES FOR THE THERAPY OF METASTATIC UROTELIAL CANCER. **2020**, 6, 4-8
- 651 Human Prostate Cancer-Associated Macrophage Subtypes with Prognostic Potential Revealed by Single-cell Transcriptomics. 1
- 650 Building a Canadian Translational Bladder Cancer Research Network. **2020**, 14, E475-E481
- 649 Precision Medicine, Artificial Intelligence, and Genomic Markers in Urology. Do we need to Tailor our Clinical Practice?. **2020**, 29, 158-167
- 648 Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?. **2021**, 7, FSO770 2
- 647 Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. **2021**, 13, 0
- 646 Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. **2021**, 15, 441-450 0
- 645 Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. **2021**, 9, 1
- 644 The Tumor Microenvironment of Bladder Cancer. **2020**, 1296, 275-290 2
- 643 Pharmacokinetics, Pharmacodynamics, and Toxicology Aspects of Immunotherapeutics. **2021**, 195-214
- 642 Practice change in the management of metastatic urothelial carcinoma after ASCO 2020. **2020**, 11, 976-982 0

- 641 Diagnosis and Management of Checkpoint Inhibitor Side Effects in Patients with Bladder Cancer: the Urologist's Perspective. **2020**, 6, 425-433
- 640 Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. **2020**, 2020, 5269787 2
- 639 Identification of an Immune Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer.
- 638 Immunotherapy in urothelial cancer. **2019**, 13, 209-213
- 637 Urothelial Cancer of the Upper Urinary Tract. **2020**, 539-550
- 636 Immunotherapy and Radiosurgery. **2020**, 423-436
- 635 Cancers urologiques. **2020**, 147-158.e8
- 634 Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study (Preprint).
- 633 Metastasiertes Urothelkarzinom. **2020**, 1-11
- 632 Immunotherapy in Advanced Prostate Cancer. **2020**, 16, 44
- 631 Tumoren van de urinewegen. **2020**, 489-507
- 630 Cancer Immunotherapy Confers a Global Benefit. **2020**, 1-48
- 629 Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies. **2021**, 21, 589 4
- 628 Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma. **2021**,
- 627 The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. **2021**, 81, 95-95 12
- 626 Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. **2021**, 6
- 625 Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence. **2021**, 13, 3
- 624 Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. **2021**, 11, 761110 2

623	ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group.. 2021 , 28, 4474-4484	0
622	Safety, Efficacy and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. 2021 ,	4
621	Clinical Outcomes of Three or More Courses of First-line Chemotherapy for Metastatic Urothelial Carcinoma.. 2021 , 1, 459-464	
620	A Case of Muscle-Invasive Bladder Cancer With Pelvic Lymph Node Involvement Treated With Pembrolizumab and Subsequent Radical Cystectomy and Maintained No Evidence of Disease After Surgery.. 2021 , 13, e19375	0
619	Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis.. 2020 , 9, 4173-4187	
618	[Quality of life in immune checkpoint inhibitors trials]. 2020 , 107, 830-842	
617	Autocrine Signaling by Receptor Tyrosine Kinases in Urothelial Carcinoma of the Bladder.	
616	Immunotherapy for Metastatic Urothelial Cancer. 2021 , 201-213	
615	Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update.	
614	Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing.	0
613	Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors.	0
612	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy. 2021 , 132, 374-383	6
611	Clinical Utility of Bladder Cancer Biomarkers. 2020 , 1, 62-67	
610	Immune Checkpoint Inhibitors for Urothelial Cancer: An Update on New Therapies. 2018 , 35, S62-S64	
609	Management of Advanced Bladder Cancer: An Update. 2018 , 9, 410-416	7
608	Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis. 2019 , 35, 101-115	1
607	Bladder Cancer Academy 2019 Selected Summaries. 2019 , 21, 23-28	2
606	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. 2017 , 15, 466-477	3

- 605 [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis]. **2020**, 23, 927-940
- 604 Safety and tolerability of Miltuximab - a first in human study in patients with advanced solid cancers. **2021**, 9, 86-100 1
- 603 [Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors ?Based Combination Therapy]. **2021**, 24, 513-518
- 602 First-line maintenance immunotherapy in advanced urothelial cancers: Practice changing implications of the JAVELIN bladder 100 trial. **2021**, 37, 295-296
- 601 Immune escape mechanisms and immunotherapy of urothelial bladder cancer. **2021**, 7, 485-500 2
- 600 The Hippo pathway: an emerging role in urologic cancers. **2021**, 9, 301-317 1
- 599 Expression and clinicopathological significance of Foxp3 and VISTA in cervical cancer. **2021**, 13, 10428-10438
- 598 Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway. **2021**, 19, 283 1
- 597 Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. **2021**, 4
- 596 Advances in Immunotherapy and the TGF- β Resistance Pathway in Metastatic Bladder Cancer. **2021**, 13, 0
- 595 OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts. **2021**, 11, 650678 0
- 594 The Cost of Enfortumab Vedotin Wastage Due to Vial Size-A Real-World Analysis. **2021**, 13, 0
- 593 Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. **2021**, 12, 710943 1
- 592 Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab. **2021**,
- 591 Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis. **2021**, 169, 103534 0
- 590 Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology. **2021**, 1
- 589 CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer.. **2021**, 2, 514-530 3
- 588 A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma. **2021**, 0

587	Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma.. 2021 , 9, 762478	0
586	Insights into artificial intelligence in clinical oncology: opportunities and challenges. 2021 , 1	
585	Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives. 2021 ,	0
584	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. 2021 , 27, 59	2
583	A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer.. 2021 , 12, 764184	0
582	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. 2021 ,	0
581	Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach. 2021 , 13,	3
580	Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer. 2021 , 21, 1267	2
579	Development of a model to demonstrate the impact of National Institute of Health and Care Excellence cost-effectiveness assessment on health utility for targeted medicines. 2021 , 31, 417	1
578	A case of long-term complete remission of locally advanced T4 bladder cancer treated with pembrolizumab.. 2022 , 41, 101959	1
577	The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.. 2021 , 12, 792691	1
576	Dual inhibition of TGF- β and PD-L1: a novel approach to cancer treatment. 2021 ,	1
575	Urotheltumoren: Immuntherapien auf dem Prfstand.	
574	Rational combination with an immunotherapy backbone in genitourinary cancers. 2020 , 31, 4	0
573	Immune Checkpoint Blockade for Genitourinary Malignancies and the Abscopal Response. 2021 , 551-559	
572	Landscape of Immunotherapy in Genitourinary Malignancies.. 2021 , 1342, 143-192	0
571	Immunological Significance of Alternative Splicing Prognostic Signatures for Bladder Cancer.	
570	The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression. 2022 , 63-73	

569	Avelumab in locally advanced or metastatic urothelial carcinoma.. 2022 ,	0
568	Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines.. 2021 , 243, 110367	0
567	Biomarkers for predicting the efficacy of immune checkpoint inhibitors.. 2022 , 13, 481-495	1
566	Ongoing Trial and Clinical Trial Endpoint Debate: The Role of Pathologic Response as a Surrogate of Survival Endpoints. 2022 , 75-89	
565	Biomarkers Predicting Outcomes Before and After Neoadjuvant Immune Checkpoint Inhibition Therapy for Muscle-Invasive Bladder Cancer. 2022 , 37-54	
564	Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity.. 2022 ,	5
563	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes.. 2021 , 169, 103570	4
562	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.. 2021 , 146, 112516	7
561	Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy.. 2021 , 7, 100346	0
560	Pembrolizumab-induced uveitis in a patient with metastatic urothelial carcinoma. 2019 , 6, 92	
559	Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer.. 2020 , 9, 6537-6545	1
558	Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy.. 2022 , 11,	1
557	A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report.. 2022 , 101, e28339	1
556	Research progress of tumor targeted drug delivery based on PD-1/PD-L1.. 2022 , 616, 121527	2
555	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. 2022 , 15, 6	4
554	Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab.. 2022 , 10781552211073883	2
553	Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer.. 2022 , 14,	0
552	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.. 2022 , JCO2101485	2

551	Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma.. 2022 , 14, 17588359211068733	2
550	Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review.. 2022 , 1	1
549	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study.. 2022 ,	1
548	Background: State-of-the-Art and Ongoing Developments. 2022 , 3-11	
547	Cabozantinib Plus Nivolumab Phase I Expansion Study in Metastatic Urothelial Carcinoma Patients Refractory to Immune Checkpoint Inhibitor Therapy.. 2022 ,	1
546	Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-World Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System.. 2021 , 11, 801199	1
545	Treatment of Metastatic Bladder Cancer. 2022 , 425-441	
544	Identification and validation of a novel signature for prediction the prognosis and immunotherapy benefit in bladder cancer.. 2022 , 10, e12843	0
543	Systemtherapien beim Urothelkarzinom der Harnblase und des oberen Harntrakts. 2022 , 24, 18-21	
542	Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma.. 2022 , 23, 51	0
541	IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab.. 2022 , 14,	0
540	From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC).. 2022 , 14,	1
539	A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma.. 2021 , 9, 812422	0
538	A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.. 2022 , 29, 2072-2084	
537	Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy.. 2021 ,	1
536	Clinical Case Debate: Neoadjuvant Checkpoint Inhibition Versus Standard Chemotherapy. 2022 , 13-25	
535	The Role of Immunotherapy as Bladder-Sparing Solution for Muscle-Invasive and Non-muscle-Invasive Bladder Cancer: Current Status and Future Perspectives. 2022 , 109-122	
534	Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs).. 2022 , 29, 267-282	0

533	Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types.. 2022,	3
532	Predicting Objective Response Rate (ORR) in Immune Checkpoint Inhibitor (ICI) Therapies with Machine Learning (ML) by Combining Clinical and Patient-Reported Data. 2022, 12, 1563	1
531	Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.. 2022, 10,	3
530	Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art.. 2022, 29, 687-697	1
529	Treatment of Upper Tract Urothelial Carcinoma. 2022, 443-483	
528	Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.. 2022, 23,	5
527	New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond.. 2022, 11,	0
526	Which test for crossing survival curves? A user's guideline.. 2022, 22, 34	2
525	Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.. 2022, 10,	0
524	Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.. 2021, 103, 102333	4
523	Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer.. 2022,	
522	The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors.. 2022, 13, 811200	1
521	Immunotherapy-Induced Acute Hepatitis in the Elderly: The Case of a Patient with Urothelial Carcinoma and a Review of the Literature. 2022,	0
520	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study.. 2022, 170, 103596	0
519	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. 2022, 163, 55-65	0
518	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.. 2022, 236, 108111	6
517	Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.. 2022,	0
516	Activation of PPAR γ in bladder cancer via introduction of the long arm of human chromosome 9.. 2022, 23, 92	

515	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade.. 2022 , 12,	3
514	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day.. 2022 , 10,	0
513	Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.. 2022 , 29, 945-955	0
512	Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity.. 2022 , 59, 116657	0
511	Socio-economic burden of disease: Survivorship costs for bladder cancer.. 2022 , 32, 100326	1
510	Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.. 2021 ,	1
509	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. 2021 ,	6
508	Pembrolizumab-induced Myasthenia Gravis Relapse After Immunosuppressive Therapy.. 2022 ,	0
507	Biomarkers in muscle invasive bladder cancer.. 2022 , 107, 265-297	0
506	A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities.. 2022 , 38, e28	1
505	Radiotherapy and Systemic Anti-Cancer Treatment in Older Adults with Cancer and Frailty. 2022 , 235-264	0
504	Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment.. 2022 , 28, 1610196	
503	Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group.. 2022 , 14,	0
502	Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data.. 2022 , 14, 623-635	0
501	Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo.. 2022 , 27,	1
500	Sarcopenia and the rate of change of the neutrophil/lymphocyte ratio as predictors of pembrolizumab efficacy in advanced urothelial carcinoma.. 2022 , 33, 459-466	0
499	Immunological significance of alternative splicing prognostic signatures for bladder cancer.. 2022 , 8, e08994	
498	Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis.. 2022 , 10,	0

- 497 A Prognostic Model of Bladder Cancer Based on Metabolism-Related Long Non-Coding RNAs.. **2022**, 12, 833763 0
- 496 Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review.. **2022**, 14, 2
- 495 Development of a LAG-3 Immunohistochemistry Assay for Melanoma.
- 494 Effective Combination Immunotherapy through Vessel Normalization Using a Cancer-Targeting Antiangiogenic Peptide-Antibody Hybrid. 2100151
- 493 Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure.. **2022**, 12, 796407 0
- 492 Squamous Cell Carcinoma of Bladder.
- 491 Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study.. **2022**, 22, 168 0
- 490 A Prognostic Model for Predicting Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Bladder Urothelial Carcinoma.. **2022**, 13, 708003 0
- 489 DNA-PK inhibition and radiation promote anti-tumoral immunity through RNA Polymerase III in pancreatic cancer.. **2022**, 0
- 488 Use of Pembrolizumab in End-Stage Renal Disease: A Case Report with Complete Response.. **2022**, 15, 187-190 0
- 487 Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?. **2022**, 14, 1
- 486 The prognostic value of the derived neutrophil-to-lymphocyte ratio (dNLR) in patients treated with immune checkpoint inhibitors.. **2022**, 1 0
- 485 Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.. **2022**, 0
- 484 Anti-PD-L1 monoclonal antibody for the management of chronic disseminated intravascular coagulation secondary to a urothelial carcinoma: a case report.. **2022**, 16, 113 0
- 483 Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer.. **2022**, 1
- 482 Urothelial carcinoma with mandibular metastasis and synchronous prostate cancer.. **2022**, 15,
- 481 Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.. **2022**, JCO2102631
- 480 Neutrophil Extracellular Traps in Cancer Therapy Resistance.. **2022**, 14, 2

479	Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.. 2022 , JCO2102051	8
478	Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review.. 2022 , 1	1
477	Identification of a novel immune-related long noncoding RNA signature to predict the prognosis of bladder cancer.. 2022 , 12, 3444	1
476	Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.. 2022 , 14,	1
475	Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials.. 2022 , 14, e22942	0
474	Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting.. 2022 , 11, 2052410	1
473	Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience.. 2022 , 13, 837499	
472	Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.. 2022 , 23, 104-111	2
471	Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?. 2022 , 39, 271	0
470	Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.. 2022 , 23,	8
469	High Stromal SFRP2 Expression in Urothelial Carcinoma Confers an Unfavorable Prognosis.. 2022 , 12, 834249	
468	Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.. 2022 ,	1
467	Feasibility of [Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma.. 2022 , 1	1
466	Efficacy of pembrolizumab in a rare type of bladder cancer arising 25 years after augmentation cystoplasty.. 2022 , 15,	0
465	The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.. 2022 , 14,	0
464	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-analysis of 22 randomized controlled trials.. 2022 ,	
463	Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.. 2022 ,	0
462	Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region.. 2022 ,	0

461	[Immunotherapy in urologic oncology : Response and treatment interruptions due to adverse events in a bicentric real-world analysis].. 2022 , 1	
460	Inibitori dei checkpoint immunitari e patologia tiroidea. 2022 , 23, 125-132	
459	Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy.. 2022 ,	0
458	Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.. 2022 ,	1
457	Recent Advances in Medical Therapy for Urological Cancers.. 2022 , 12, 746922	2
456	Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer.. 2022 , 14,	0
455	The role of tumour microenvironment-driven miRNAs in the chemoresistance of muscle-invasive bladder cancer-a review.. 2022 ,	0
454	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.. 2022 , 20, 44	9
453	Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.. 2021 ,	1
452	Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series.. 2021 ,	0
451	Predictive biomarkers for the efficacy of nivolumab as B-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial.. 2022 , 22, 378	0
450	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. 2022 , 13, 1878	1
449	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.. 2022 , 13, 1797	0
448	Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review.. 2022 ,	0
447	Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?. 2022 , 19, 101387	1
446	C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.. 2022 , 167, 13-22	0
445	Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.. 2022 , 19, 101383	0
444	Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.. 2022 , 46, 100848	0

443	Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma.. 2021 , 13,	1
442	The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.. 2021 ,	0
441	The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer. 2021 ,	0
440	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. 2021 ,	1
439	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. 2021 , 12, 773168	1
438	Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma.. 2021 , 8, 673918	1
437	Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies.. 2021 , 9,	2
436	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.. 2021 , 14, 109	2
435	Favorable response to pembrolizumab in granulocyte colony-stimulating factor-producing upper urinary tract urothelial carcinoma.. 2022 , 5, 108-112	
434	Case Report: Erdafitinib-induced Central Serous Chorioretinopathy. 2021 , 99,	1
433	The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.. 2021 , 12, 793964	0
432	Practice-changing publications: Muscle-invasive bladder cancer.. 2021 ,	
431	A case of complete response following the administration of pembrolizumab and metastasectomy for lung and bone metastases of bladder cancer.. 2022 , 5, 92-94	1
430	ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. 2021 ,	4
429	Model-Based Characterization of the Bidirectional Interaction between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.. 2021 ,	
428	Combinations will lead the way in immunotherapy for bladder cancer. 2020 , 3, 603	1
427	Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data.. 2022 ,	1
426	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.. 2022 , 13, 1935	3

425	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism.. 2022 , 13, 835510	1
424	Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.. 2022 , 3, e137	0
423	Expression and Prognostic Implication of PD-L1 in Patients with Urothelial Carcinoma with Variant Histology (Squamous Differentiation or Micropapillary) Undergoing Radical Cystectomy.. 2022 , 10,	
422	Recent Therapeutic Advances in Urothelial Carcinoma: A Paradigm Shift in Disease Management.. 2022 , 103683	0
421	Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumour.. 2022 ,	1
420	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.. 2022 , 13, 862084	0
419	Immunologic Gene Sets Reveal Features of the Tumor Immune Microenvironment and Predict Prognosis and Immunotherapy Response: A Pan-Cancer Analysis.. 2022 , 13, 858246	0
418	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.. 2022 , 5, e227722	1
417	Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature.. 2022 , 12, 816444	1
416	Use of immunotherapy in clinical management of genitourinary cancers - a review.. 2022 , 31, 100564	0
415	New emerging targets in advanced urothelial carcinoma: is it the primetime for personalized medicine?. 2022 , 103682	2
414	DataSheet_1.pdf. 2021 ,	
413	Table_1.docx. 2021 ,	
412	Data_Sheet_1.docx. 2020 ,	
411	Image_1.tif. 2020 ,	
410	Image_2.tif. 2020 ,	
409	Table_1.xls. 2020 ,	
408	Table_1.xlsx. 2019 ,	

407 Table_2.xlsx. 2019,

406 Table_3.xlsx. 2019,

405 Table_4.xlsx. 2019,

404 Table_5.xlsx. 2019,

403 Table_6.xlsx. 2019,

402 Table_7.xlsx. 2019,

401 DataSheet_1.csv. 2020,

400 Image_1.tif. 2020,

399 Image_2.tif. 2020,

398 Image_3.tif. 2020,

397 Image_4.tif. 2020,

396 Image_5.tif. 2020,

395 Image_6.tif. 2020,

394 Image_7.tif. 2020,

393 Image_8.tif. 2020,

392 Image_9.tif. 2020,

391 Table_1.DOCX. 2020,

390 Data_Sheet_1.docx. 2019,

389 Data_Sheet_1.CSV. **2020**,

388 Data_Sheet_2.doc. **2020**,

387 Image_1.TIF. **2020**,

386 Image_2.TIF. **2020**,

385 Image_3.TIF. **2020**,

384 Image_4.TIF. **2020**,

383 Image_5.TIF. **2020**,

382 Image_6.TIF. **2020**,

381 Image_7.TIF. **2020**,

380 Image_8.PNG. **2020**,

379 Data_Sheet_1.docx. **2018**,

378 Image_1.TIF. **2019**,

377 Table_1.doc. **2019**,

376 Image_1.tif. **2020**,

375 Image_2.tif. **2020**,

374 Table_1.docx. **2020**,

373 Table_2.docx. **2020**,

372 Table_3.docx. **2020**,

371 Table_4.docx. **2020**,

370 Data_Sheet_1.PDF. **2020**,

369 Image_1.tiff. **2020**,

368 Data_Sheet_1.doc. **2019**,

367 Image_1.TIF. **2019**,

366 Image_2.TIFF. **2019**,

365 Image_3.TIF. **2019**,

364 Table_1.DOCX. **2019**,

363 Table_10.DOCX. **2019**,

362 Table_11.DOCX. **2019**,

361 Table_12.docx. **2019**,

360 Table_2.DOCX. **2019**,

359 Table_3.DOCX. **2019**,

358 Table_4.DOCX. **2019**,

357 Table_5.docx. **2019**,

356 Table_6.DOCX. **2019**,

355 Table_7.DOCX. **2019**,

354 Table_8.DOCX. **2019**,

353	Table_9.DOCX. 2019 ,	
352	Image_1.TIF. 2020 ,	
351	Data_Sheet_1.zip. 2020 ,	
350	Data_Sheet_1.pdf. 2019 ,	
349	Table_1.XLSX. 2019 ,	
348	Table_2.xlsx. 2019 ,	
347	Data_Sheet_1.PDF. 2019 ,	
346	DataSheet_1.docx. 2020 ,	
345	Progress in the development of tissue-based biomarkers for urothelial cancer.. 2022 ,	
344	Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.. 2022 ,	
343	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. 2022 ,	2
342	Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.. 2022 , 183, 201-223	
341	The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy.. 2022 , 14, 17588359221094879	0
340	A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma. 2022 , 1-14	
339	Immune Checkpoint Inhibitors in Cancer Therapy. 2022 , 29, 3044-3060	11
338	Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab.. 2022 ,	1
337	Pyroptosis-Related Patterns Predict Tumor Immune Landscape and Immunotherapy Response in Bladder Cancer.. 2022 , 9, 815290	0
336	A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients. 2022 , 13,	0

335	Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.. 2022 , 14, 1641-1651	0
334	Impact of salvage cytotoxic chemotherapy on prognosis in patients with recurrence after radical cystectomy: a multi-institutional retrospective study.. 2022 , 22, 75	
333	Genomics and Immunomics in the Treatment of Urothelial Carcinoma. 2022 , 29, 3499-3518	0
332	Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study.. 2022 , 14,	2
331	Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?. 2022 , 11, 1614	
330	MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.. 2022 ,	4
329	Efficacy of Pembrolizumab in Patients with Variant Urothelial Carcinoma: A Multicenter Retrospective Study. 2022 ,	0
328	Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.. 2022 , 22, 497	0
327	Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.. 2022 , 45, 590-595	0
326	Long-Term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated with Neoadjuvant Chemotherapy. 2022 ,	
325	Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction.. 2022 ,	0
324	Molecular targets in urinary bladder cancer. 1-5	
323	Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.. 2022 , 54, 1339-1349	0
322	Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.. 2022 , 169, 74-81	2
321	CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.. 2022 , 70, 103345	0
320	Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.. 2022 , 12, 876098	0
319	Bladder Cancer. 2022 , 51-65	0
318	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis.. 2022 , 7, 100474	1

- 317 Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. **2022**, 14, 2460
- 316 Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors.. **2022**, 22, 551 0
- 315 Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. **2022**, 14, 2470 0
- 314 Neurological Manifestations of Myocarditis.. **2022**,
- 313 Development of a LAG-3 immunohistochemistry assay for melanoma.. **2022**, 1 1
- 312 Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.. **2022**, 10, 1 1
- 311 Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.. **2022**, 10, 0
- 310 Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. **2022**, 1-16 1
- 309 Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma.
- 308 PD-L1 expression and FGFR -mutations among Danish patients diagnosed with metastatic urothelial carcinoma - a retrospective and descriptive study. 0
- 307 A novel strategy for treatment of bladder cancer: Antibody-drug conjugates. 63,
- 306 New Treatment Options for Patients With Bladder Cancer. **2022**, 20, 570-572 1
- 305 Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma. **2022**, 0
- 304 Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis. 0
- 303 T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancer.
- 302 Immunologische Biomarkerforschung in der Uronkologie (Beispiel Urothelkarzinom).
- 301 Insights on recent innovations in bladder cancer immunotherapy. 0
- 300 Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.

299	Immuno-Oncologic Treatment of Genitourinary Malignancies. 2022 , 729-735	
298	Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. 12,	0
297	Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor. 2022 , 17, 329-341	1
296	Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer. 12,	1
295	Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab. 2022 , 23,	0
294	Complete and long-lasting response to immunotherapy. 2022 , 101, e28940	0
293	Radiopharmaceuticals as Novel Immune System Tracers. 2022 , 100936	
292	Tumor-derived C-C motif ligand 2 (CCL2) induces the recruitment and polarization of tumor-associated macrophages and increases the metastatic potential of bladder cancer cells in the postirradiated microenvironment. 2022 ,	0
291	Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy. Volume 14, 1945-1960	0
290	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.	0
289	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.	9
288	Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR).	1
287	Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients. 2022 , 12,	0
286	The carbonic anhydrase inhibitor acetazolamide inhibits urinary bladder cancers via suppression of β -catenin signaling.	
285	Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. 12,	0
284	Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma. 2022 , 24,	
283	Lower neutrophil-to-lymphocyte ratio and positive programmed cell death ligand-1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma.	0
282	A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.. 2022 , 236, 153983	1

- 281 The dynamic roles of the bladder tumour microenvironment. 0
- 280 Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. Publish Ahead of Print, 0
- 279 A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma. 13, 1
- 278 Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. 0
- 277 A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy. 12, 0
- 276 Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. 2022, 4
- 275 Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. OF1-OF9 0
- 274 CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. 12, 0
- 273 Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. 2022, 2022, 1-27 0
- 272 Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome. 0
- 271 Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab. 0
- 270 Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. 0
- 269 The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma. 2022, 10, 1609 1
- 268 Clinical potential of the Hippo-YAP pathway in bladder cancer. 12, 0
- 267 EDITORIAL COMMENT. 2022, 165, 104-105 0
- 266 Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. 2022, 14, 3440 0
- 265 Immunosenescence, inflammaging, and cancer immunotherapy efficacy. 1-12 1
- 264 The Relationship of Pyroptosis-Related Genes, Patient Outcomes, and Tumor-Infiltrating Cells in Bladder Urothelial Carcinoma (BLCA). 13, 0

- 263 Classifying cGAS-STING activity links chromosomal instability with immunotherapy response in metastatic bladder cancer. 0
- 262 Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. **2022,**
- 261 Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy. **2022,** 43, 14-21
- 260 Urothelial Carcinoma (Bladder Cancer and Upper Tracts). **2023,** 309-329.e4
- 259 Clinical Eosinophil-Associated Genes can Serve as a Reliable Predictor of Bladder Urothelial Cancer. 9, 2
- 258 Evaluation of Thyroid Dysfunction Associated with the Use of Molecular Targeted Antineoplastic Drugs Using the Japanese Adverse Drug Event Report Database. **2021,** 47, 437-444
- 257 Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. **2022,** 11, 4373
- 256 Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes. 0
- 255 Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study. 0
- 254 Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System. **2022,** 10, 1842 2
- 253 Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments. 12, 0
- 252 Recent Advances and Challenges in Cancer Immunotherapy. **2022,** 14, 3972 3
- 251 A comprehensive single-cell breast tumor atlas defines cancer epithelial and immune cell heterogeneity and interactions predicting anti-PD-1 therapy response. 0
- 250 First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. **2022,** 1 1
- 249 High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications. 0
- 248 The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. **2022,** 11, 4523 0
- 247 Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. **2022,** 10, 2005
- 246 A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.

- 245 Limited predictive impact of tumor size dynamics on further tumor shrinkage after 4 cycles of first-line chemotherapy in patients with advanced urothelial carcinoma. **2022,**
- 244 Immune-related adverse events in urothelial cancer patients: Adjustment for immortal time bias. 0
- 243 Phototherapy with cancer-specific nanoporphyryn potentiates immunotherapy in bladder cancer. 2
- 242 Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment. **2022,** 5, e2227211 0
- 241 Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020).
- 240 Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. **2022,** 12, 1229
- 239 Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy. **2022,**
- 238 Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now. **2022,** 23, 1269-1287 3
- 237 Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. 12, 2
- 236 Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors. **2022,**
- 235 Site-Specific Differences in PD-1 Blockade Success and Biomarkers in Urothelial Carcinoma Treated with Pembrolizumab. **2022,** 0
- 234 T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. **2022,** 23, 8590 0
- 233 Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis.
- 232 Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. 12, 0
- 231 Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis. 1-11 0
- 230 Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. 0
- 229 An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next. **2022,** 90, 191-205 1
- 228 Enfortumab vedotin in the treatment of urothelial cancers and beyond. 1

227	The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma.	
226	First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer.	1
225	EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.	1
224	Association of the time to immune checkpoint inhibitor (ICI) initiation and outcomes with second line ICI in patients with advanced urothelial carcinoma. 2022,	0
223	Computational design of PD-L1 small molecule inhibitors for cancer therapy.	2
222	Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report.	
221	Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis. 13,	
220	Intravital Optical Imaging for Immune Cell Tracking after Photoimmunotherapy with Plasmonic Gold Nanostars.	0
219	NCCN Guidelines Insights: Bladder Cancer, Version 2.2022. 2022, 20, 866-878	9
218	Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Urothelkarzinoms. 2022, 28, 782-791	
217	A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer.	
216	Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome. 2022, 81, 104323	
215	Treatment with opioids in patients with locally advanced or metastatic urothelial carcinoma and matched non-cancer controls. 2022, 40, 411.e9-411.e18	0
214	The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma. 2022, 26, 387-398	0
213	The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy. 2022, 11,	0
212	Development of a Simple and Objective Prognostication Model for Patients with Advanced Solid Malignant Tumors Treated with Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. 2022, 17, 583-589	0
211	Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade. 12,	0
210	Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study. 2022, 10, 2243	0

- 209 The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. **2022**, 7, 100577 ○
- 208 Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma. **2022**, 175, 43-53 ○
- 207 Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies. **2022**, 11, ○
- 206 Construction and Analysis of an Immune-Related Gene Prognostic Index for Bladder Cancer. **2022**, 10, 82-99 ○
- 205 Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. **2022**, 29, 107327482211112 ○
- 204 Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells. **2022**, 5, 1
- 203 The era of personalized treatments: Updates on immunotherapy within urothelial of bladder cancer. **2022**, 16, 117-120 ○
- 202 A novel immunotherapy prognostic score for patients with pretreated advanced urinary tract carcinoma from the subgroup analysis of the SAUL study. The urinary TrAct Carcinoma score (ITACA). ○
- 201 Case Report: Neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis. 12, ○
- 200 Immune status for monitoring and treatment of bladder cancer. 13, ○
- 199 Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. 12, ○
- 198 First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis. **2022**, 45, 407-414 ○
- 197 Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. **2022**, 7, 2
- 196 Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease. **2022**, 11, 5171 ○
- 195 Remarkable response to gemcitabine rechallenge in advanced urothelial carcinoma: a case report. Publish Ahead of Print, ○
- 194 Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma. ○
- 193 Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt/mTOR and Cyclin/CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines. **2022**, 23, 10996 ○
- 192 Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the Real-Life Setting. **2022**, 15, 1154 ○

191	Outcomes of Immune Checkpoint Inhibitors in Patients with Cancer and a Poor Performance Status #445. 2022 , 25, 1440-1442	0
190	Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report. 12,	0
189	Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.	0
188	Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma. 13,	0
187	Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. 2022 , 101, e30151	0
186	Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.	0
185	Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer. 13,	0
184	High Serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. 2022 ,	0
183	Comparative assessment of early mortality risk upon immunecheckpoint inhibitors alone or in combinations with other agents across solid malignancies: a systematic review and meta-analysis. 2022 ,	5
182	Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a Pan-RAS inhibitor.	0
181	Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma. 2022 , 8,	0
180	Targeting L-type amino acid transporter 1 in Urological Malignancy: current status and future perspective. 2022 ,	0
179	THE DNA DAMAGE INDUCED IMMUNE RESPONSE: IMPLICATIONS FOR CANCER THERAPY. 2022 , 103409	0
178	Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial.	1
177	Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors. 2022 , 81, 102265	1
176	ONE COURSE OF PEMBROLIZUMAB AFTER RADIATION THERAPY WAS VERY EFFECTIVE AGAINST METASTATIC BLADDER CANCER AND CR WAS CONFIRMED: A CASE REPORT. 2021 , 112, 220-223	0
175	Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer. 2022 , 201-231	0
174	Predictive Biomarkers in the Management of Bladder Cancer: Perspectives in an Evolving Therapeutic Landscape. 2022 , 3, 245-257	0

- 173 Proton pump inhibitors/potassium-competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma. ○
- 172 Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada. **2022**, 29, 7587-7597 ○
- 171 Controlling Nutritional Status (CONUT) Score and Sarcopenia as Mutually Independent Prognostic Biomarkers in Advanced Urothelial Carcinoma. **2022**, 14, 5075 ○
- 170 Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review). **2022**, 12, 205-216 ○
- 169 Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+). **2022**, 14, 5286 ○
- 168 Disparities in access to novel systemic therapies in patients with urinary tract cancer: Propagating access, policies and resources uniformly. **2022**, ○
- 167 Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab. Volume 15, 1259-1269 ○
- 166 Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data. ○
- 165 Urothelial Cancer. 1-11 ○
- 164 Precision Medicine in the Treatment of Locally Advanced or Metastatic Urothelial Cancer: New Molecular Targets and Pharmacological Therapies. **2022**, 14, 5167 ○
- 163 Bifunctional anti-PD-L1/TGF- β II agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. **2022**, 20, ○
- 162 Precision Medicine in Oncology Drug Development. 1-15 ○
- 161 Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis. **2022**, 22, ○
- 160 GemcitabinePaclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy. **2022**, 23, 12119 1
- 159 Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival. 28, 5750-5763 ○
- 158 Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial. ○
- 157 HER2 expression in urothelial carcinoma, a systematic literature review. 12, ○
- 156 Monoclonal Antibody and Targeted Toxin Therapy. 1-31 ○

- 155 Both radiographical and pathological lymph node statuses are independent predictors for survival following neoadjuvant chemotherapy and radical cystectomy for cT3/4 or cN+ bladder cancer. ○
- 154 Immunotherapy and Modern Radiotherapy Technique for Older Patients with Locally Advanced Head and Neck Cancer: A Proposed Paradigm by the International Geriatric Radiotherapy Group. **2022**, 14, 5285 ○
- 153 A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome. ○
- 152 Circ_0084043-miR-134-5p axis regulates PCDH9 to suppress melanoma. 12, ○
- 151 Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment. 12, ○
- 150 High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+/regulatory T-cell infiltration. **2022**, 22, ○
- 149 Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020. **2022**, 7, 100593 ○
- 148 The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy. **2022**, 156, 113839 ○
- 147 Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer. ○
- 146 The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis. 12, ○
- 145 Engaging stemness improves cancer immunotherapy. **2022**, 216007 1
- 144 Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma. 13, ○
- 143 Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma. **2022**, 14, 5431 ○
- 142 The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status. Volume 15, 1321-1330 ○
- 141 Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma. ○
- 140 French AFU Cancer Committee Guidelines Update 2022-2024: Upper urinary tract urothelial cancer (UTUC). **2022**, 32, 1164-1194 ○
- 139 Spatial Immunophenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. **2022**, ○
- 138 Treatment rechallenge with immune checkpoint inhibitors in advanced urothelial carcinoma. **2022**, ○

- 137 Primary lung cancer treatable with radical resection after complete remission with pembrolizumab therapy following gemcitabine and carboplatin chemotherapy for multiple metastases of bladder cancer. ○
- 136 PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?. **2022**, 103435 1
- 135 Hypoxia-Inducible Factor-2-Altered Urothelial Carcinoma: Clinical and Genomic Features. **2022**, 29, 8638-8649 ○
- 134 French AFU Cancer Committee Guidelines [Update 2022]2024: Muscle-Invasive Bladder Cancer (MIBC). **2022**, 32, 1141-1163 ○
- 133 Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer. ○
- 132 Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors. 1
- 131 Combining PARP Inhibitor With Immunotherapy Does the Promise of Preclinical Data Translate to Clinic?. ○
- 130 Genomic and clinical prognostic factors in patients with advanced urothelial carcinoma receiving immune checkpoint inhibitors. **2022**, ○
- 129 Longitudinal Modulation of Loco-Regional Immunity in Ovarian Cancer Patients Receiving Intraperitoneal Chemotherapy. **2022**, 14, 5647 ○
- 128 The cancer behavior and current treatment strategy for upper urinary tract cancer. **2022**, 33, 161 ○
- 127 The Legacy of RTOG/NRG Protocols in Shaping Current Bladder Preservation Therapy in North America. **2023**, 33, 26-34 ○
- 126 Outcomes of Patients with Advanced Urothelial Carcinoma after Anti-programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study. **2023**, 47, 48-57 ○
- 125 Biological Stratification of Invasive and Advanced Urothelial Carcinoma. **2023**, 50, 69-80 ○
- 124 Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival. **2023**, 39, 100558 ○
- 123 Interdisciplinary Approach in Genitourinary Cancers. **2022**, ○
- 122 BCG-Unresponsive Bladder Cancer: New Frontiers in the Treatment Landscape. 2-9 ○
- 121 Immune landscape and immunotherapy for penile cancer. 13, ○
- 120 Design and reporting of phase III oncology trials with prospective biomarker validation. ○

119	Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. 12,	0
118	Novel insights toward histone lysine methyltransferases in cancer therapy: from epigenetic regulation to selective drugs. 2022,	0
117	Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond. 1-19	0
116	Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms.	0
115	Therapeutic Antibodies in Cancer Treatment in the UK. 2022, 23, 14589	0
114	Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.	0
113	A novel prognostic model based on cellular senescence-related gene signature for bladder cancer. 12,	0
112	Change of genitourinary cancer patients' perception and expectations over the course of pharmacotherapy. 2022, 17, e0278039	0
111	Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers. 2022, 22, 997-1008	0
110	Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report. 12,	1
109	Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives. 039156032211399	0
108	Cost of bladder cancer in Lebanon before and after the economic collapse: A probabilistic modeling study.	0
107	Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. 2022,	0
106	Immune Checkpoint Inhibitor Therapy in 'Oncology. 2022, 4, 579-597	2
105	Switch Maintenance Therapy for Metastatic Urothelial Carcinoma. 2022, 8, 359-369	0
104	Case report: Complete response of a bladder cancer patient with multiple hepatic and pelvic metastases treated by nab-paclitaxel combined with sintilimab. 12,	0
103	Integrated molecular analyses of an interferon- β -based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. 2022, 8, e12102	0
102	Prognostic nutritional index of early post-pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma. 2022, 25,	0

- 101 Five-year outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: experience from real-world clinical practice. **2022**, ○
- 100 CD3^{high} and FoxP3⁺ tumor-infiltrating lymphocytes in the invasive margin as a favorable prognostic marker in patients with invasive urothelial carcinoma of the bladder. Publish Ahead of Print, ○
- 99 IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. **2022**, 22, ○
- 98 Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients. ○
- 97 Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients. ○
- 96 Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context. Volume 15, 1519-1529 ○
- 95 Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology Trials. ○
- 94 A novel immunotherapy prognostic score for patients with pretreated advanced urinary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score. ○
- 93 A rare case of bladder cancer that metastasized to brain, heart, and lung lymph nodes benefited from immunotherapy. **2022**, 20, ○
- 92 IDH2 stabilizes HIF-1 β -induced metabolic reprogramming and promotes chemoresistance in urothelial cancer. ○
- 91 PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer. ○
- 90 Optimal Systemic Treatment of Advanced Bladder Cancer Calls for a Multidisciplinary Approach. **2023**, 15, 559 ○
- 89 The role of switch maintenance therapy in urothelial cancers. **2023**, 15, 175628722211477 ○
- 88 Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer. **2023**, 16, 175628482211482 ○
- 87 Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer. Volume 12, 1-16 ○
- 86 Increasing cure rates of solid tumors by immune checkpoint inhibitors. **2023**, 12, ○
- 85 Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer. **2023**, 15, 566 ○
- 84 Strahlentherapie und Immuntherapie. **2023**, 1-20 ○

83	The Effects of Clonal Heterogeneity on Cancer Immunosurveillance. 2023 , 7,	0
82	Microbiota in Cancer Immunotherapy: The Next Milestone of Immuno-oncology?. 2023 , 269-287	0
81	Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. 2023 , 11, 107	1
80	Immunotherapy for Urothelial Carcinoma. 2023 , 1-12	0
79	The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis. 2023 , 15, 284	1
78	Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.	0
77	Contemporary Systemic Therapies in Urothelial Carcinoma. 2023 ,	0
76	Urothelkarzinom der Harnblase: systemische Therapie des metastasierten Urothelkarzinoms. 2023 , 1-13	0
75	Tumor immunology. 2023 , 245-452	0
74	Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. 2023 , 11, e005924	0
73	Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study.	1
72	Mint3-targeted therapy: A novel therapeutic strategy for urothelial carcinoma. 2023 , 3,	0
71	Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis. 12,	0
70	Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. 2023 , 11, e005007	0
69	Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.	0
68	Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis. 12,	0
67	BASP1 is a prognostic biomarker associated with immunotherapeutic response in head and neck squamous cell carcinoma. 13,	0
66	Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario. 2023 , 22, 153303382311597	0

- 65 Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. **2023**, ○
- 64 Management of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma: Expert Opinion from an Indian Panel via Delphi Consensus Method. ○
- 63 HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. ○
- 62 Current status of immunotherapy in the adjuvant treatment of invasive urothelial carcinoma. **2023**, 17, 26-30 ○
- 61 Evolving systemic management of urothelial cancers. **2023**, 35, 186-199 ○
- 60 New late-emphasis and combination tests based on infimum and supremum logrank statistics with application in oncology trials. ○
- 59 Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study. ○
- 58 The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer. ○
- 57 Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score. **2023**, 83, 432-440 ○
- 56 The Future of Antibody-Drug Conjugates in Urothelial Cancer. **2023**, 3, 137-159 ○
- 55 Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma. **2023**, 119, 110158 ○
- 54 Integrated multiomics analyses unveil the implication of a costimulatory molecule score on tumor aggressiveness and immune evasion in breast cancer: A large-scale study through over 8,000 patients. **2023**, 159, 106866 ○
- 53 Randomized phase II trial in prostate cancer with hormone-sensitive Oligometastatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol. **2023**, 40, 100613 ○
- 52 Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer. **2023**, 23, ○
- 51 Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma at a Tertiary Referral Center in Portugal. **2023**, 36, 145-146 ○
- 50 Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immuno-oncologic Predictive Factors. **2023**, 30, 203-210 ○
- 49 Integrative analysis of immune infiltration and microenvironment characteristics in renal clear cell carcinoma induced by cell senescence. ○
- 48 Knowledge-map analysis of bladder cancer immunotherapy. ○

- 47 Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma. **2023**, 15, 1066 ○
- 46 Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis. **2023**, 9, 264-274 ○
- 45 Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis. **2023**, 23, ○
- 44 Overexpression of KMT9B Is Associated with Aggressive Basal-like Muscle-Invasive Bladder Cancer. **2023**, 12, 589 ○
- 43 Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity. ○
- 42 A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). **2023**, 16, ○
- 41 Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma. ○
- 40 Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis. **2023**, 21, ○
- 39 PD-L1 and MHC Class I Expression in High-grade Ovarian Cancers, Including Platinum-resistant Recurrences Treated With Checkpoint Inhibitor Therapy. **2023**, 31, 197-203 ○
- 38 Developing an m5C regulator-mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer. 14, ○
- 37 Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors. **2023**, 6, e230490 ○
- 36 Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. ○
- 35 Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial. **2023**, 24, 347-359 ○
- 34 ACER2 forms a cold tumor microenvironment and predicts the molecular subtype in bladder cancer: Results from real-world cohorts. 14, ○
- 33 Financial toxicity from newly approved second-/ third-line agents in metastatic urothelial carcinoma. ○
- 32 Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. 14, ○
- 31 Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities. **2023**, ○
- 30 Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma. **2023**, 28, 17-26 ○

- 29 In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer. **2023**, 40, ○
- 28 Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade. ○
- 27 Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. **2023**, 16, ○
- 26 Single Drug Therapy of PD-1/PD-L1 Checkpoint Inhibitors for Advanced Urothelial Bladder Cancer. 36, 29-35 ○
- 25 The usage of Pembrolizumab in Metastatic Urothelial Carcinoma. 36, 331-340 ○
- 24 Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study. ○
- 23 Evodiamine Exhibits Anti-Bladder Cancer Activity by Suppression of Glutathione Peroxidase 4 and Induction of Ferroptosis. **2023**, 24, 6021 ○
- 22 European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. **2023**, ○
- 21 Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle-invasive bladder cancer. ○
- 20 Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma. **2023**, 35, 166-177 ○
- 19 Efficacy and safety of TACE combined with lenvatinib and PD -1 inhibitors for unresectable recurrent HCC : A multicenter, retrospective study. ○
- 18 Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020. **2023**, 15, 2069 ○
- 17 Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. 13, ○
- 16 Molecular subtypes, tumor microenvironment infiltration characterization and prognosis model based on cuproptosis in bladder cancer. 11, e15088 ○
- 15 Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward. 1-12 ○
- 14 Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer. 14, ○
- 13 Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis. 13, ○
- 12 Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases. 13, ○

- 11 Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma. ○
- 10 The prognostic value of thyroid hormone levels in immunotherapy-treated patients with metastatic urothelial carcinoma. **2023**, ○
- 9 Association of patient-reported pain with survival in bladder cancer: a post-hoc analysis of the iBLAD trial. 1-6 ○
- 8 Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a systematic review and meta-analysis. ○
- 7 Alteration in expression of pattern-recognition-receptors-signaling- pathways-related genes is associated with immune microenvironment and predicts clinical outcomes in bladder cancer. ○
- 6 Influence of gender on the pathophysiology and treatment of urological malignancies. **2023**, 793-803 ○
- 5 Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?. **2023**, 12, 3014 ○
- 4 Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies. **2023**, 64, 202 ○
- 3 A Case of Advanced Multifocal Cholangiocarcinoma With Excellent Response to Pembrolizumab. **2023**, ○
- 2 Immunotherapy with or without targeted therapy for metastatic upper tract urothelial carcinoma: case report and literature review. **2023**, 9, e15813 ○
- 1 A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study. **2023**, 187, 104016 ○